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Summary 
Antibodies (abs) to myelin oligodendrocyte glycoprotein (MOG) are known to induce 
demyelination in experimental animals and are found in a proportion of patients with different 
inflammatory diseases of the CNS.  
In the first part of this thesis, the clinical spectrum of patients with MOG-specific abs 
was examined. To this end a cell-based assay (CBA) with transient transfection of full-length 
MOG was further optimized. A total of 260 adult patients from the outpatient clinic of the 
Institute of Clinical Neuroimmunology were analyzed for reactivity to human MOG by using 
this assay and 17 patients (6.5 %) tested positive. Recognized epitopes were determined 
with mutated variants of MOG. Some of these patients with abs to MOG were clinically 
classified as neuromyelitis optica spectrum disorders (NMOSD) and optic neuritis (ON), 
diseases in which it is already known that MOG-specific abs can occur. One of the 17 
patients with MOG-specific abs had features overlapping with both multiple sclerosis (MS) 
and NMOSD and fulfilled only partially the criteria of these diseases. This patient had a 
severe disease course and underwent brain biopsy. The histopathological analysis revealed 
a MS type II pathology which is characterized by the deposition of the terminal complement 
complex c9neo. Moreover, this pattern of MS is expected to be antibody-mediated but the 
recognized antigen has not yet been identified. Here we describe for the first time the 
histopathology of MOG-antibody associated encephalitis and our findings suggest that the 
demyelination observed in our patient is mediated by abs to MOG. This could not directly be 
proven since MOG-specific abs of this patient did not cross-react with rodent MOG. The 
presence of MOG-specific abs in classical MS is a controversial issue since years. Inspired 
by our case report with MOG-antibody associated MS type II pathology, we specifically 
analyzed a cohort of MS patients selected for having severe ON and/or myelitis; we found 
that 5 % of these patients have abs to MOG. 
 The second part of this thesis aimed to analyze the pathogenic properties of human 
abs to MOG. To this end, patients with abs to MOG showing cross-reactivity to rodent MOG 
were identified. Abs to MOG from two patients were affinity purified. These abs bound human 
MOG by ELISA and in our CBA, stained myelin in situ and induced EAE exacerbation in vivo. 
As an additional experimental approach, recombinant abs to MOG were generated from one 
of these patients. To this end, MOG-specific B lymphocytes in the peripheral blood and in 
vitro differentiated B lymphocytes were identified by the employment of MOG tetramers and 
subsequently single-cell sorted, Ig chains were cloned and recombinant abs were produced. 
The recombinant abs obtained from these cells recognized MOG by ELISA with low affinity, 
but neither bound MOG in our CBA nor stained brain tissue. Moreover, the recombinant 
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antibody with the highest affinity for MOG was tested in vivo for its potential pathogenicity but 
no EAE exacerbation was observed.  
Together, this thesis extends the knowledge about the clinical spectrum of adult 
patients with abs to MOG and describes the histopathology of anti-MOG associated 
encephalomyelitis. Further, it shows that abs to MOG, affinity purified from the peripheral 
blood of patients diagnosed with demyelinating disease, can enhance pathology in an animal 
model. 
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Zusammenfassung 
Antikörper gegen das  Myelin-Oligodendrozyten-Glykoprotein (MOG) wirken in Tiermodellen 
demyelinisierend und kommen in manchen Patienten mit unterschiedlichen entzündlichen 
Erkrankungen des ZNS vor. 
Im ersten Teil dieser Arbeit wurde das klinische Spektrum von erwachsenen Patienten mit 
MOG-spezifischen Antikörpern untersucht. Zu diesem Zweck wurde ein zellbasierter Assay 
mit transienter Transfektion von voll-längen MOG weiter optimiert. Insgesamt wurden 260 
erwachsene Patienten aus der ambulanten Klinik des Instituts für Klinische 
Neuroimmunologie auf die Reaktivität von hMOG getestet: 17 Patienten (6,5%) mit 
Antikörpern gegen MOG wurden identifiziert. Die Antigen Epitope wurden Anhand von 
unterschiedlichen MOG Varianten analysiert. Einige der Patienten mit Antikörper gegen 
MOG wurden mit Neuromyelitis optica Spektrum-Erkrankungen (NMOSD) und Neuritis nervi 
optici (ON) diagnostiziert. Bei Patienten mit diesen Krankheiten ist bereits bekannt, dass 
MOG-spezifische Antikörper auftreten können. Einer von 17 Anti-MOG-positiven Patienten 
zeigte eine Überlappung an Krankheitssymptomen von Multipler Sklerose (MS), als auch 
NMOSD-spezifischen Eigenschaften und erfüllte daher nur teilweise die klassifizierenden 
Kriterien dieser Erkrankungen. Da dieser Patient einen schweren Krankheitsverlauf hat, 
wurde ihm eine Hirnbiopsie entnommen. Die histopathologische Analyse ergab ein MS-Typ-
II-Pattern, das durch Ablagerung des terminalen Komplementkomplexes c9neo 
gekennzeichnet ist. Weiterhin ist bekannt, dass die Erkrankung vom Typ-II Antikörper 
assoziert ist, wobei deren Antigene überwiegend noch nicht identifiziert wurden. Diese Arbeit 
beschreibt zum ersten Mal die Histopathologie eines Patienten mit MOG-Antikörpern 
assoziierter Enzephalitis. Die Ergebnisse weisen darauf hin dass die Demyelinisierung in 
diesem Patienten von MOG-Antikörpern vermittelt wird. Dies konnte nicht direkt in 
Tiermodellen nachgewiesen werden, da die MOG-spezifische Antikörper dieses Patienten 
keine Kreuzreaktivität gegen Maus und Ratten MOG aufwiesen. Die Detektion von 
Antikörpern gegen MOG bei klassischer MS ist seit Jahren ein umstrittenes Thema. Daher 
wurde eine weitere  Kohorte von MS-Patienten, die mit schwerer optischer Neuritis und / 
oder Myelitis diagnostiziert wurden, ausgewählt und in dieser Arbeit auf MOG-Antikörpern 
untersucht. In 5% dieser Patienten wurden die entsprechenden Antikörper nachgewiesen. 
 Der zweite Teil dieser Arbeit zielte darauf ab, die pathogenen Eigenschaften der 
menschlichen Antikörper gegen MOG zu analysieren. Zu diesem Zweck wurden Patienten 
mit Antikörpern gegen MOG, die eine Kreuzreaktivität gegen Maus und Ratten MOG zeigten, 
identifiziert. Es konnten MOG-spezifische Antiköper von zwei Patienten aufgereinigt werden. 
Diese Antikörper zeigten sowohl im ELISA, als auch in einem Zell-basierten Assay eine 
Reaktivität gegen hMOG. Zusätzlich färbten diese Antikörper Hirngewebe und induzierten 
eine Verschlechterung der EAE (Experimentelle autoimmune Enzephalomyelitis) in vivo. Als 
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zusätzlicher experimenteller Ansatz wurden rekombinante Antikörper gegen MOG von einem 
dieser Patienten hergestellt. Hierfür wurden MOG-spezifische B Zellen in PBMCs (Peripheral 
blood mononuclear cells) und in vitro differenzierten B-Lymphozyten des Patienten durch 
den Einsatz von MOG-Tetrameren identifiziert, auf Einzelzell-Ebene sortiert, die IgG Ketten 
kloniert und rekombinante Antikörper wurden produziert. Die aus diesen Zellen erhaltenen 
rekombinanten Antikörper erkannten MOG mit geringer Affinität im ELISA aber zeigten 
weder im Zell-basierten Assay, noch im Hirngewebe Reaktivität gegen MOG. Darüber hinaus 
wurde der rekombinante Antikörper mit der höchsten Affinität für MOG in vivo auf seine 
potentielle Pathogenität getestet. Im Gegensatz zu den aufgereinigten Antikörpern, 
induzierte dieser Antikörper keine Verschlechterung der EAE. 
Diese Arbeit erweitert das aktuelle Wissen über das klinische Spektrum von 
erwachsenen Patienten mit Antikörpern gegen MOG und beschreibt die Histopathologie der 
mit diesen Antikörpern assoziierten Enzephalitis. Darüber hinaus konnte gezeigt werden, 
dass Antikörper gegen MOG, die aus dem Blut von Patienten mit einer demyelinisierenden 
Erkrankung aufgereinigt wurden,  die Pathologie im Tiermodell verschlechtern können. 
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1 Introduction 
 Inflammatory demyelinating diseases of the central nervous system      1.1
(CNS) 
Inflammatory demyelinating diseases of the CNS comprise a spectrum of diseases including 
multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), optic neuritis 
(ON) and acute disseminated encephalomyelitis (ADEM). They consist in a clinically 
heterogeneous group of diseases regarding age of onset, clinical course, treatment, 
magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) features. It is sometimes 
difficult to make an accurate diagnosis, especially at disease onset, since these diseases 
sometimes show overlapping features in clinical, MRI or serum/CSF findings (Figure 1).   
MS is the most common chronic inflammatory disease of the CNS. In the majority of MS 
patients, the disease is characterized at the beginning by a relapsing-remitting course 
(RRMS), which is followed after several years by a secondary progressive phase (SPMS). In 
some patients the disease is progressive from the onset (PPMS) (Confavreux, Vukusic et al. 
2000). During the early stages of MS, inflammatory demyelination leads to the formation of 
focal plaques localized in the white matter, while later stages are characterized by a diffusion 
of demyelination in the cerebral and cerebellar cortex, as well as by degenerative processes 
in the white and grey matter (Kutzelnigg, Lucchinetti et al. 2005). Since T cells are able to 
induce a blood-brain barrier disruption and to induce CNS inflammation (Kebir, Kreymborg et 
al. 2007), MS has been for long time considered a T-cell driven disease, however, there are 
many evidences that B cells and autoantibodies play a key role in MS pathogenesis 
(Krumbholz, Derfuss et al. 2012, Hohlfeld, Dornmair et al. 2016).  
The term NMOSD was introduced in 2007 after the revision of the diagnostic criteria for 
neuromyelitis optica (NMO) due to the discovery of NMO-immunoglobulin G (IgG) or 
Aquaporin-4 (AQP4)-specific antibodies (abs) (see below) (Wingerchuk, Lennon VA et al. 
2006). Patients diagnosed with NMOSD have recurrent, isolated longitudinal extensive 
transverse myelitis (LETM, spinal cord lesion that extends over three or more vertebrae) or 
ON. These conditions can be associated or not with autoimmune disorders or brain lesions 
(hypothalamic, corpus callosal, periventricular, or brainstem)  typical for NMO (Wingerchuk, 
Lennon VA et al. 2007).  
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Figure 1: CNS inflammatory demyelinating diseases. Most patients present with clinically isolated 
syndrome (CIS) and subsequently develop MS or rare MS variants, such as Marburg, Balo or Schilder 
disease (MS spectrum). A first demyelinating event could also herald NMO or NMO-like disease, such 
as isolated (recurrent) ON or transverse myelitis. A third group of patients develop monophasic 
demyelinating diseases such as ADEM, isolated ON or transverse myelitis. Modified from (Reindl, Di 
Pauli et al. 2013). 
ON is a demyelinating inflammation of the optic nerve that can appear as an isolated 
condition or in association with MS or NMOSD. Clinical features of this disease include a 
sudden unilateral vision loss, visual field loss, abnormal color vision, reduced contrast 
sensitivity function as well as the Uhthoff’ phenomenon that consists in a decrease of visual 
acuity due to high body temperature (Hickman, Dalton et al. 2002). Patients who experienced 
an episode of unilateral ON have a possibility of the 38% to develop MS in the next ten 
years. This percentage increases in the case of brain lesions in MRI (Beck, Trobe et al. 
2003). 
The original definitions for ADEM have been updated in 2013 (Krupp, Tardieu et al. 2013). 
This disease occurs predominantly during early childhood and has often a monophasic 
course. Monophasic ADEM is characterized by single polyphasic CNS event with 
enchephalopathy (alteration in behavior or consciousness) and inflammatory demyelination 
during the first three months after disease onset. A small proportion of patients is diagnosed 
with multiphasic ADEM (Neuteboom, Boon et al. 2008) in which two ADEM episodes are 
separated by at least three months. 
The patients who participated in this study are adults diagnosed with MS, ON, NMOSD or 
encephalomyelitis.   
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 Role of B cells and autoantibodies 1.1.1
Several evidences suggest that B cells and autoantibodies are key players in inflammatory 
demyelinating diseases of the CNS:  
 the CSF of MS patients is characterized by the presence of locally produced oligoclonal 
bands (OCB) (Obermeier, Mentele et al. 2008) and clonally expanded B cells (Von 
Büdingen, Gulati et al. 2010);  
 demyelinating areas of MS lesions in a subset of patients show IgG and activated 
complement deposition (Lucchinetti, Brück et al. 2000);  
 plasma exchange is beneficial in a subset of patients with MS type II pathology (Keegan, 
König et al. 2005); 
 B-cell follicles have been reported  in the meninges of some patients with progressive MS 
(Serafini, Rosicarelli et al. 2004);  
 active NMO lesions showed IgM deposition and complement activation (Lucchinetti, 
Mandler et al. 2002, Misu, Höftberger et al. 2013);  
 B-cell depleting therapies with anti-CD20 show a reduction of relapses in a subset of 
patients with MS and NMO (Hauser, Waubant et al. 2008, Krumbholz, Derfuss et al. 
2012, Trebst, Jarius et al. 2014)  
Apart from their role to generate antibody-producing cells, B cells perform a spectrum of 
additional functions which are crucial for the pathogenesis of MS and related disorders 
(Figure 2) (Krumbholz, Derfuss et al. 2012, Hoffmann and Meinl 2014, Krumbholz and Meinl 
2014). 
The important role of autoantibodies in demyelinating diseases of the CNS is highlighted by 
the discovery of pathogenic IgG in NMO patients.  These abs bind selectively to the water 
channel AQP4, localized on astrocytes (Lennon, Wingerchuk et al. 2004) and are considered 
a valuable biomarker in distinguishing NMO from MS. Their pathogenicity has been 
demonstrated by transfer studies in which human NMO IgG or human sera containing AQP4-
specific abs where injected in mice with experimental autoimmune encephalomyelitis (EAE), 
(Bradl, Misu et al. 2009, Saadoun, Waters et al. 2010, Saini, Rifkin et al. 2013, Wu, Zhou et 
al. 2013), the animal model that most closely resembles clinical and neuropathological 
features of human MS. Moreover, several in vivo experiments showed that autoantibodies 
can induce disease exacerbation only after a breaching of the blood-brain barrier (Genain, 
Nguyen et al. 1995, Derfuss, Parikh et al. 2009, Mayer and Meinl 2012). 
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Figure 2: Inflammatory and regulatory functions of B cells. B cells exert various pro-inflammatory 
and immunoregulatory functions: they produce autoantibodies that can induce complement activation 
and ADCC. They are involved in inflammatory cytokine production (i.e. TNF, IL-6, LT), antigen-
presentation and follicular antigen-transport. On the other hand, they produce anti-inflammatory 
cytokines (IL-10, IL-35 and TGF-β), which induce expansion of Treg cells, reduce Th1 and Th17 
differentiation, and inhibit macrophage (M) and dendritic cell (DC) activity. Furthermore, B cells 
produce abs with potential immunoregulatory function and neurotrophic factors. Modified from 
(Hoffmann and Meinl 2014). 
 
 Therapeutic interventions targeting B cells and autoantibodies 1.1.2
The discovery of the pathogenic role of B cells and autoantibodies in CNS inflammation 
provided a strong rationale for the development and use of new therapeutic approaches over 
the last decades: 
B cell-depleting monoclonal antibodies 
Different monoclonal abs (mAb) target the CD20 molecule which is expressed throughout 
different maturation stages of the human B-cell lineage, from pre-B cells to early 
plasmablasts, and is lost during plasmacell differentiation (Krumbholz, Derfuss et al. 2012). 
Rituximab, a chimeric mAb, depletes CD20+ B cells efficiently from the circulation and 
reduces inflammatory brain lesions and clinical relapse in RRMS patients (Hauser, Waubant 
et al. 2008). It can reduce the levels of AQP4-specific abs in some but not all patients with 
NMO (Jarius and Wildemann 2010) and is also effective as a second line therapy in NMO 
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patients in which it does not affect AQP4-specific abs levels (Pellkofer, Krumbholz et al. 
2011).                                                                                                                                                      
Other drugs targeting the CD20 molecule include humanized mAbs: ocrelizumab reduces the 
relapse rate and disease progression in RRMS (Hauser, Comi et al. 2015), while 
ofamtumumab reduces MRI lesions in RRMS patients  (Sorensen, Lisby et al. 2014). These 
mAbs appear to have similar therapeutic efficiency in MS as rituximab. B cells are also 
targeted, simultaneously with T cells by the anti-CD52 mAb alemtuzumab, recently approved 
for the treatment of RRMS (Cohen, Coles et al. 2012). 
Targeting antibodies 
 Abs can be removed from the circulation by plasma exchange or immunoadsorption (IA). 
The main difference between these two approaches is that the latter one allows the specific 
removal of abs and immune complexes by implying columns containing hydrophobic amino 
acids (Yoshida, Tamura et al. 2000). Plasma exchange and IA are used for steroid-resistant 
relapse in MS and NMO (Heigl, Hettich et al. 2013, Krumbholz and Meinl 2014).  
 
 Myelin Oligodendrocyte Glycoprotein (MOG) 1.2
Myelin Oligodendrocyte Glycoprotein (MOG) was identified for the first time as the target of 
in-vitro demyelinating abs obtained from guinea pigs immunized with homologues CNS 
tissue (Lebar, Lubetzki et al. 1986). Full length human MOG (hMOG) consists of 218 amino 
acids and belongs to the immunoglobulin superfamily (Pham-Dinh, Matteit et al. 1993). It is 
expressed exclusively in the CNS where it is localized on the outer surface of myelin (Figure 
3) and represents less than 0.05% of total myelin proteins (Brunner, Lassmann et al. 1989).       
The exact function of MOG is not known, however, it has been shown recently that MOG 
might be involved in the modulation of axon growth and survival since it directly interacts with 
the nerve growth factor (NGF) (von Büdingen, Mei et al. 2015). MOG might also be able to 
regulate the classical complement pathway through its interaction with the complement 
component C1q (Johns and Bernard 1997). The structure and localization of this protein 
suggests also a role as adhesion molecule (Clements, Reid et al. 2003), however, a MOG 
knockout mice did not show any obvious phenotype (Delarasse, Daubas et al. 2003).   
Introduction 
 
6 
 
Figure 3: Distribution of CNS myelin proteins. Typical myelin proteins are found at the internode: 
Proteolipid protein (PLP) and Myelin basic protein (MBP) are the major myelin proteins, the 
quantitatively minor MOG is found at the outermost surface of the myelin sheath. Figure taken from 
(Mayer and Meinl 2012). 
Among numerous antigens that have been proposed as antibody targets in MS and related 
disorders, MOG has received the greatest attention for the following reasons:  it is localized 
on the outermost myelin sheath (Brunner, Lassmann et al. 1989) and is therefore easily 
accessible for pathogenic abs present in the extracellular milieu (Mayer and Meinl 2012);  
studies in animal models showed that MOG is the target of demyelinating abs (see below). 
 
 MOG-specific abs in Experimental Autoimmune Encephalomyelitis 1.3
(EAE) 
A first evidence of the potential involvement of MOG in the pathogenesis of demyelination 
derived from a study performed in guinea pigs with chronic relapsing EAE: the sera of these 
animals were able to induce, after injection in the subarachnoid space, in vivo demyelination 
in normal rats and this demyelinating activity directly correlated with their anti-MOG antibody 
titers (Linington and Lassmann 1987). Subsequently, evidences from different animal models 
showed that, upon active immunization, MOG is able to trigger both an antibody-mediated 
demyelinating as well as an encephalitogenic T-cell response in Lewis rats  (Adelmann, 
Wood et al. 1995), SJL/J mice and primates (Bourquin, Schubart et al. 2003, 't Hart, Laman 
et al. 2004). Studies performed in C57Bl/6 mice, on the other hand, led to interesting results 
since in this animal model only the immunization with human MOG, and not rat MOG, 
induced B-cell-dependent EAE (Marta, Oliver et al. 2005).  
Introduction 
 
7 
 Pathogenic potential of abs to MOG: evidences from animal studies 1.3.1
Anti-MOG mAbs are pathogenic both in rats (Schluesener, Sobel et al. 1987, Lassmann, 
Brunner et al. 1988, Linington, Bradl et al. 1988) and in primates (Genain, Nguyen et al. 
1995) in which EAE was obtained either after active immunization with MBP or upon 
adoptive transfer of MBP-specific T cells. On the other hand, MBP-specific EAE in the 
absence of anti-MOG abs is characterized only by an inflammatory response without 
demyelination. MOG-specific abs exert their demyelinating activity in a complement 
dependent manner (Piddlesden, Lassmann et al. 1993) and require breakdown of the blood-
brain barrier to enhance pathology (Litzenburger, Fässler et al. 1998) However, recent 
publications proposed a possible effector mechanism which brought new insights in the 
sophisticated interplay that occurs between T cells, B cells and abs during disease. These 
studies showed that MOG-specific abs can trigger inflammation by increasing the antigen 
presentation to myelin-reactive T cells in the CNS and therefore promote their expansion and 
encephalitogenic differentiation (Flach, Litke et al. 2016, Kinzel, Lehmann-Horn et al. 2016).  
  
 Different detection methods of MOG-specific abs 1.4
Studies performed over the last decades to identify the occurrence of abs to MOG in 
humans, gave controversial results. This can partially be explained by methodical variations 
regarding antigen preparation and antibody detection. 
 Investigation of MOG-specific abs by using ELISA or Western blot 1.4.1
Initial investigations were performed to detect the presence of abs to MOG in MS patients: a 
first study aimed to determine by ELISA the presence of MOG-specific abs in the serum and 
the CSF of 30 MS patients and showed that these abs not only occurred in the CSF of a 
subset of MS patients but they were also present in control groups (Xiao, Linington et al. 
1991). In a more recent report abs to MOG were analyzed by using refolded rat MOG 
expressed in Escherichia coli. IgG and IgM to MOG could not be detected neither in MS 
patients nor in controls (Gori, Mulinacci et al. 2011). Abs to MOG were also detected by 
using MOG peptides: autoantibodies from MS patients and normal healthy controls (HC) 
were affinity purified and tested for reactivity against a panel of MOG peptides (Haase, 
Guggenmos et al. 2001). The authors found that epitope specificity was quite heterogeneous 
in both groups and that only one of the 17 tested MS patients and none of the nine HC abs 
were able to bind full length MOG expressed in its native state on the surface of fibroblasts. 
Therefore, even though abs recognizing MOG peptides can be detected both in MS patients 
and in HC, only a subset of patients has also abs that bind the full length protein and these 
are absent in healthy individuals. This is an important observation since it is known from 
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animal experiments that only abs that recognize cell-bound MOG, in its native and 
glycosylated state, are able to induce demyelination in EAE models (Brehm, Piddlesden et 
al. 1999, Ohtani, Kohyama et al. 2011).                                                         
Several studies analyzed abs to MOG by Western Blot, in which MOG is in its denatured 
state: MOG-specific abs were detected in MS patients, HC (Lindert, Haase et al. 1999, 
Reindl, Linington et al. 1999) and patients with clinically isolated syndrome (CIS). These 
authors found that CIS patients with MBP- or MOG-specific abs, had a higher relapse risk 
and a higher probability to develop MS (Berger, Rubner et al. 2003). However, these results 
could not be confirmed by other studies which used the same methods (Kuhle, Pohl et al. 
2007, Pelayo, Tintoré et al. 2007). 
 Abs to conformational-intact MOG 1.4.2
The observation that only MOG-specific abs that are able to bind to conformational-intact 
MOG can determine demyelination in vivo highlights the importance of the use of cell-based 
assays (CBA) when detecting these abs in serum and CSF.  
Abs to MOG in children. An important milestone in this context is represented by the studies 
performed by O’Connor and colleagues (O'Connor, McLaughlin et al. 2007): the authors 
used a sensitive assay based on self-assembling radiolabeled tetramers in which  the native 
folding of the protein was guaranteed by in vitro translation system with endoplasmic 
reticulum microsomes. They could detect abs to MOG in a subset of ADEM patients but not 
in adult MS. These results were subsequently confirmed in other reports in which antibody 
detection was performed by using flow cytometry and immunocytochemistry (McLaughlin, 
Chitnis et al. 2009, Lalive, Hausler et al. 2011). The prevalence of MOG-specific abs was 
higher in a subset of patients with a younger age at disease onset and during a first episode 
of CNS demyelination (Brilot, Dale et al. 2009, McLaughlin, Chitnis et al. 2009, Fernandez-
Carbonell, Vargas-Lowy et al. 2015). Moreover, longitudinal analysis of anti-MOG reactivity 
revealed that, while in pediatric MS abs to MOG tend to remain stable over time (Probstel, 
Dornmair et al. 2011), in ADEM patients they disappear and this was associated with a more 
favorable clinical outcome (Di Pauli, Mader et al. 2011, Probstel, Dornmair et al. 2011). 
Further studies revealed that abs to conformational-intact MOG are also present in children 
with recurrent ON (Rostasy, Mader et al. 2012). 
Abs to MOG in adults.  A subset of AQP4-IgG negative NMO/NMOSD patients harbor a 
MOG-directed immune response and seem to have a  more favorable clinical outcome when 
compared to patients with a typical AQP4-antibody mediated disease (Mader, Gredler et al. 
2011, Kitley, Woodhall et al. 2012, Kitley, Leite et al. 2013). However, this finding could not 
be confirmed by more recent studies (Kim, Woodhall et al. 2015, Jarius, Ruprecht et al. 
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2016). Abs to MOG have also been observed in adults with bilateral and recurrent ON 
(Ramanathan, Reddel et al. 2014) and rarely in patients with anti-N-methyl-D-aspartate 
(NMDA)-receptor encephalitis (Titulaer, Hoftberger et al. 2014). 
Epitope mapping on conformational-intact MOG. The mapping of epitopes is important to 
understand autoantibody function and pathogenicity. Moreover, knowing the autoantibody 
epitope target and its conservation among species, can contribute to develop epitope-
specific therapies and pathogenic studies in animal models. The use of a panel of MOG 
mutants allowed in a previous study to get an insight into the epitope determination on native 
human MOG in different pediatric patient groups (Mayer, Breithaupt et al. 2013): human abs 
to MOG recognize epitopes that connect the β strands of the extracellular IgV-like domain of 
MOG. The most frequently recognized epitope was P42, which is not present in rodent MOG. 
In addition, only 20% of patients had abs that recognize the epitope His103; Ser104 which is 
the main target of the 8-18C5 antibody used in animal studies. In some cases, the 
recognition of specific amino acids can induce epitope-specific effects: behavioral studies in 
rats showed that the injection of two different mAbs recognizing different epitopes on the 
smaller form of the glutamate decarboxylase (GAD65) can induce distinct neurological 
effects (Hampe, Petrosini et al. 2013). On the other hand, the analysis of antibody binding to 
MOG did not reveal any relevant difference between the analyzed patient groups (Mayer, 
Breithaupt et al. 2013).  
 
 Possible pathogenic mechanisms of MOG-specific abs in humans 1.5
Evidences for a pathogenic role of human abs to MOG have emerged from several studies. 
MOG-specific abs from children with CIS or ADEM have a natural killer meditated cytotoxic 
effect on MOG-expressing cells in vitro, moreover, antibody-dependent cell-mediated 
cytotoxicity (ADCC) correlated with antibody titer (Brilot, Dale et al. 2009). The majority of 
abs to MOG has the complement-activating IgG1 isotype which can activate complement 
and bind to the Fc receptors (McLaughlin, Chitnis et al. 2009). Another study showed that 
abs to MOG are able to induce at high titers the activation of the complement cascade, 
leading to the formation of the terminal complement complex (TCC) and to the internalization 
of these abs. This resulted in a complement dependent lysis of MOG-transfected cells 
(Mader, Gredler et al. 2011). In addition, a recent report revealed that purified IgG from MOG 
antibody-positive patients are able to induce cytoskeletal changes in cultured 
oligodendrocytes, however, no cell death was observed (Dale, Tantsis et al. 2014).  
A possible pathogenic role of MOG-specific abs arises also from in vivo experiments. 
Transfer of sera from MS patients with MOG-specific abs to EAE rats showed an 
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enhancement of demyelination (Zhou, Srivastava et al. 2006). On the other hand, the 
injection of total IgG obtained from MOG-antibody positive NMO patients into mouse brains 
induced myelin changes and altered expression of axonal proteins that were reversible 
(Saadoun, Waters et al. 2014). Furthermore, this study did not reveal any complement 
involvement, suggesting therefore a different pathogenic mechanism. 
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 Aims of this project 1.6
The main aims of this study were: 
 Definition of the clinical spectrum of adult patients with abs to conformational-intact MOG, 
with a particular focus on the anti-MOG reactivity in adult MS and the histopathological 
features of MOG-associated encephalomyelitis. 
 
 Investigation of the pathogenic potential of patient derived MOG-specific abs and of the 
antibody repertoire. MOG-specific abs were obtained by combining  different 
experimental approaches: 
- Affinity purification  
- Isolation of MOG-specific B cells from peripheral blood with MOG-tetramers and 
generation of recombinant abs. 
Affinity purified and recombinant abs were subsequently analyzed for binding to MOG in 
a CBA, by ELISA and for binding to myelin in situ by immunohistochemistry. The 
pathogenic potential of these abs was investigated by in vivo transfer experiments in 
Lewis rats upon determination of antibody cross-reactivity to rodent MOG.  
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2  Materials and Methods 
 Materials 2.1
 Oligonucleotides 2.1.1
All oligonucleotides used in this study were synthesized by Metabion (Martinsried, Germany). 
Table 1: Primer for MOG and vector backbones 
Description Name Sequence
ratMOG full lenght ratMOG-for 5'GGTGTGTGGAGCCTTTCTCTGC
ratMOG full lenght ratMOG-rev 5'CTTAGCTCTTCAAGAAACTGTCC
wt hMOG soluble_Cterm AviTag wtMOGtetr-for-in 5'GCATATCTCCTGGGAAGAACGCTACAGGCATGG
wt hMOG soluble_Cterm AviTag wtMOGtetr-rev-in 5'CCATGCCTGTAGCGTTCTTCCCAGGAGATATGC
wt hMOG soluble_Cterm AviTag wtMOGtetr-for-out 5'AAGCTTGGGCAGTTCAGAGTGATAGG
wt hMOG soluble_Cterm AviTag wtMOGtetr-rev-out
5'GC GGC CGC TCA GTG GTG GTG GTG GTG GTG 
GCCGCTGCCGCCGCTAGGGCTCACC CAGTATAG
CMV promoter CMV-for 5'CGCAAATGGGCGGTAGGCGTG
pTT5 backbone pTT5-for 5'GGGGTGAGTACTCCCTCTCAAAAGC
 
 
Primer for single-cell analysis 
Description Name Sequence
RT Primer scRT-HG 5´GGGCTCAACTTTCTTGTCCA
RT Primer scRT-Cmu 5´GGGACGAAGACGCTCACTT
RT Primer scRT-AID 5´GCCAGACCTGTGTTCCTTCT
RT Primer scRT-Kappa 5´CTGTAGGTGCTGTCCTTGCT
RT Primer scRT-Lambda 5´CATTCTGTAGGGGCCACTGT
Outer primer V-Heavy1-for-out 5’ACAGGTGCCCACTCCCAGGTGCAG
Outer primer V-Heavy3-for-out 5’AAGGTGTCCAGTGTGARGTGCAG
Outer primer V-Heavy4/6-for-out 5’CCCAGATGGGTCCTGTCCCAGGTGCAG
Outer primer V-Heavy5-for-out 5’CAAGGAGTCTGTTCCGAGGTGCAG
Outer primer V-Kappa1/2-for-out 5’ATGAGGSTCCCYGCTCAGCTGCTGG
Outer primer V-Kappa3-for-out 5’CTCTTCCTCCTGCTACTCTGGCTCCCAG
Outer primer V-Kappa4-for-out 5’ATTTCTCTGTTGCTCTGGATCTCTG
Outer primer scHG-rev-out 5´AGGTGTGCACGCCGCTG
Outer primer scKappa-rev-out 5’CACACAACAGAGGCAGTTCC
Inner primer V-Heavy1/5/7-for-in 5’CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG
Inner primer V-Heavy1-for-in 5’CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGGAG
Inner primer V-Heavy3-for-in 5’CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG
Inner primer V-Heavy4-for-in 5’CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG
Inner primer V-Kappa-pan-for-in 5‘ATGACCCAGWCTCCABYCWCCCTG
Inner primer scHG-rev-in 5’AGTTCCACGACACCGTCAC
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Description Name Sequence
2246_D7 IGVH cloning 2246_IGVH_D7-for
5‘GGCGGCTCCGCGGTGGGTCCTGTCCCAGGTGCAGCT
GCAGGAGTCGG
2246_D7 IGVH cloning 2246_IGVH_D7-rev
5'CCAGAGGTCGACCTGGAGCAGGGCGCCAGGGGGAA
GACCGATGGGCCCTTGGTGGAAGCTGAGGAGACGG 
2246_D7 IGVK cloning 2246_IGVK_D7-for
5'GGCTCCGAGGCGCGCGATGTGACCTCCAGATGACCC
AGTCTCCATCCTCCCTGTCTGCATCTGTAGG
2246_D7 IGVK cloning 2246_IGVK_D7-rev
5'GGAAGATGAAGACAGATGGCGCCGCCACAGTTCGTT
TGATTTCCACCTTGGTCCCTCC
2246_E6 IGVH cloning 2246_IGVH_E6-for
5'GGCGGCTCCGCGGTGGGTCCTGTCCGAGGTGCAGTT
GGTGGAGAGGGGGGGGGGGTTGGTTCAGCCTGGAGG
2246_E6 IGVH cloning 2246_IGVH_E6-rev
5'CCAGAGGTCGACCTGGAGCAGGGCGCCAGGGGGAA
GACCGATGGGCCCTTGGTGGAAGCTGAGGAGACGG 
2246_E6 IGVK cloning 2246_IGVK_E6-for
5'GGCTCCGAGGCGCGCGATGTGACATCCAGATGACCC
AGTCACCAAGCAGCCTGAGCGCCAGCGTGGGCGACA
2246_E6 IGVK cloning 2246_IGVK_E6-rev
5'GCTCATCAGATGGCGGGAAGATGAAGACAGATGGC
GCCGCCACAGTTTGTCTGATCTCC
2246_E3 IGVH cloning 2246_IGVH_E3-for
5'GGCGGCTCCGCGGTGGGTCCTGTCCCAGGTGCAGCT
GGTGCAGAGCGGCGCGGAAGTGAAACGCCCGGGGG
2246_E3 IGVH cloning 2246_IGVH_E3-rev
5'CCAGAGGTCGACCTGGAGCAGGGCGCCAGGGGGAA
GACCGATGGGCCCTTGGTGGAGGCTGAGGAGACGGTT
2246_E3 IGVK cloning 2246_IGVK_E3-for
5'GGCTCCGAGGCGCGCGATGTGAAATTGTGTTGACGC
AGTCTCC AGGCACCCTGTCTTTGTCTCCAGG
2246_E3 IGVK cloning 2246_IGVK_E3-rev
5'GGAAGATGAAGACAGATGGCGCCGCCACAGTTCGTT
TGATATCCACTTTGGTCC
2246_A2 IGVH cloning 2246_IGVH_A2-for
5'GGTAGCTGCTCCGCGGTGGGTCCTGTCCCAGGTGCA
GCTGCAGGAGTCGGGCCCAGGACTGGTGAGGGCTTC
2246_A2 IGVH cloning 2246_IGVH_A2-rev
5'CCAGGGGTCGAACCAGAGAGACCACTGTTCCTCGAC
CAGGTGTATCCCCGACACTCTCGCACAGTAATACATGG
CCGTGTCCGCTGCGGTCAC
2246_A2 IGVK cloning 2246_IGVK_A2-for
5'GCTCCGAGGCGCGCGATGTGAAATTGTGTTGACGCA
GTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAG
2246_A2 IGVK cloning 2246_IGVK_A2-rev
5'GGAAGATGAAGACAGATGGCGCCGCCACAGTTCGTT
TGACATCAACTGTGGTCCCAGGGCCGAAAGTGAATGA
2246_F6 IGVH cloning 2246_IGVH_F6-for
5'GGCGGCTCCGCGGTGGGTCCTGTCCGAGGTGCAGTT
GGTGGAGAGGGGGGGGGGGTTGGTTCAGCCTGGAGG
2246_F6 IGVH cloning 2246_IGVH_F6-rev
5’CCAGAGGTCGACCTGGAGCAGGGCGCCAGGGGGA
AGACCGATGGGCCCTTGGTGGAAGCTGAGGAGACGG
2246_F6 IGVK cloning 2246_IGVK_F6-for
5’GGCTCCGAGGCGCGCGATGTGACATCCAGATGACCC
AGTCACCAAGCAGCCTGAGCGCCAGCGTGGGCGACA
 
 Restriction enzymes 2.1.2
All restriction enzymes used in this study were purchased from NEB (New England Biolabs, Germany) 
 
Table 2: Restriction enzymes 
 
 
Enzyme Restriction site 
BssHII G'CGCGCGC
EcoRI G'AATTC
HindIII A'AGCTT
KasI G'GCGCC
NotI GC'GGCCGC
SacII CCGC'GG
SalI G'TCGAC
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 Plasmids  2.1.3
Table 3: Plasmids used for this study 
 
 
 
 
 
 
 
Vector Insert Expression Origin
pEGFP-N1 / cell surface CLONTECH Laboratories
pEGFP-N1 hMOG wt cell surface AG Meinl
pEGFP-N1 hMOG-N31D cell surface AG Meinl
pEGFP-N1 mMOG cell surface AG Meinl
pEGFP-N1 hMOG-R9G/H10Y cell surface AG Meinl
pEGFP-N1 hMOG-P42S cell surface AG Meinl
pEGFP-N1 hMOG-R86Q cell surface AG Meinl
pEGFP-N1 hMOG-S104E cell surface AG Meinl
pEGFP-N1 H103A-S104E cell surface AG Meinl
pEGFP-N1 ratMOG cell surface AG Meinl
pTT5 / soluble AG Jenne
pTT5 hMOG_Cterm AviTag soluble AG Meinl
pTT5 hMOG-gly soluble AG Meinl
pTT5 mMOG soluble AG Krishnamoorthy
pTT5 ratMOG soluble AG Krishnamoorthy
pTT5 NF155 soluble AG Meinl
pTT5 NF186 soluble AG Meinl
pTT5 omgP soluble AG Meinl
pTT5 8-18C5_IGVH soluble AG Dornmair
pTT5 8-18C5_IGVK soluble AG Dornmair
pTT5 AB3_IGVH soluble AG Dornmair
pTT5 AB3_IGVK soluble AG Dornmair
pTT5 2246_D7_IGVH soluble AG Meinl
pTT5 2246_D7_IGVK soluble AG Meinl
pTT5 2246_E6_IGVH soluble AG Meinl
pTT5 2246_E6_IGVK soluble AG Meinl
pTT5 2246_E3_IGVH soluble AG Meinl
pTT5 2246_E3_IGVK soluble AG Meinl
pTT5 2246_A2_IGVH soluble AG Meinl
pTT5 2246_A2_IGVK soluble AG Meinl
pTT5 2246_F6_IGVH soluble AG Meinl
pTT5 2246_F6_IGVK soluble AG Meinl
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 Antibodies 2.1.4
Table 4: Antibodies used in this study 
 
 
Table 5: Other reagents used for flow cytometry 
 
 
 
Target Specificity Catalogue Nr. Source Provider Conjugate
MOG / mouse C.Linington, Glasgow /
MOG / mouse AG Meinl /
MOG / human AG Dornmair /
human CD3 RM 1907S rabbit Neomarkers /
human CD8 M7103 mouse DAKO /
human CD20 MS 340S mouse Neomarkers /
humann CD68 MO814 mouse DAKO /
human CD19 555413 mouse BD Pharmingen PE
human CD27 25027942 mouse eBioscience PE-Cy7
human CD38 48-0388-41 mouse eBioscience V450
mouse B220 45045280 rat eBioscience PerCP
human Ig RPM 1003 sheep Amersham /
human IgG (H +L) 109066098 goat Jackson Immuno Research Biotin
mouse IgG (H+L) 115066003 goat Jackson Immuno Research Biotin
human IgG BA3000 goat Vector Laboratories biotin
human IgM 17999842 mouse eBioscience APC
human IgM 48999841 mouse eBioscience V450
human IgG1 905428 mouse Southern Biotech Biotin
human IgG2 906008 mouse Southern Biotech Biotin
human IgG3 921008 mouse Southern Biotech Biotin
human IgG4 920008 mouse Southern Biotech Biotin
human IgG (H+L) 109036003 goat Jackson Immuno Research HRP
mouse IgG (H+L) 715036150 donkey Jackson Immuno Research HRP
Histidine A70581VL mouse Sigma-Aldrich HRP
human C9 neo / rabbit P.Morgan, Glasgow /
B7 / mouse P.Morgan, Glasgow /
p22phox sc-20781 rabbit Santa Cruz /
PLP MCA 839G mouse Serotec /
CNPase SMI91 mouse Sternberer Monoclonals /
Neurofilament AB 1981 mouse Chemicon /
GFAP Z334 rabbit DAKO /
Aquaporin 1 and 4 sc20810 rabbit Santa Cruz /
Name Conjugate Catalogue Nr. Provider
Propidium Iodide / P4170 Sigma-Aldrich
Streptavidin FITC 11431787 eBioscience
Streptavidin Dye Light 649 16190084 Jackson Immuno Research
TO-PRO-3 Iodide / T3605 Invitrogen Life Technologies
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  Methods 2.2
 Molecular biological methods 2.2.1
2.2.1.1 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
cDNA from single cell sorted B cells was obtained by using the Qiagen One Step RT-PCR Kit 
(Qiagen, Germany). The use of this kit allows both the reverse transcription and the PCR 
amplification to take place in the same reaction mix in a “one step” reaction. The reaction 
was performed according to the protocol provided by the manufacturer and by using gene 
specific primers (RT primers) as described in (Beltran, Obermeier et al. 2014).   
2.2.1.2 Polymerase chain reaction (PCR) 
IgG gene amplification. IgH and Igĸ V gene transcripts were amplified by two independent 
rounds of nested PCR. All PCR reactions were performed in 96 well plates containing a final 
volume of 20 µl per well. The first PCRs were performed with forward primer mixes specific 
for the leader region and reverse primers specific for the IgH and Igĸ gene constant regions 
(for-out and rev-out primers). 10 µl of cDNA were used as template. After the reverse 
transcription, reactions were heated to 95 ºC for 15 minutes, this allowed the activation of the 
HotStarTaq DNA polymerase of the RT-PCR enzyme mix and the simultaneous inactivation 
of the reverse transcriptase.  2 µl of the first PCR product were used as template for the 
second PCRs which were performed by using forward primer mixes specific for FWR1 and 
respective nested reverse primers specific for the IgH and Igĸ J genes or constant regions. 
These PCRs were carried out by using the Taq DNA polymerase (Roche, Penzberg, 
Germany). PCRs for IgG gene amplification were performed in cooperation with Dr. Eduardo 
Beltran from the Dornmair group of our institute. 
 
FIRST PCR using Qiagen OneStep RT-PCR kit (20µl)  
 
2 µl   10X Reaction Buffer 
0.4 mM   dNTPs 
0.2 µM   forward OUT primer 
0.2 µM   reverse OUT primer 
20 U   enzyme mix 
10 µl   cDNA template         
        
 
PCR Program 
 
 
 
       
 
 
 
 
 
Denaturation 95ºC 15 min 
  
Denaturation 94 ºC 30 sec 
Annealing 57 ºC 30 sec 
Elongation 72 ºC 55 sec 
Elongation 72 ºC 10 min 
 
  
 
30 cycles 
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SECOND nested PCR using Roche Taq reagents (20µl)   
 
2 µl   10X reaction buffer 
0.4 mM   dNTPs 
0.5 µM   forward IN primer 
0.5 µM   reverse IN primer 
1 U  TaqDNA polymerase                 
2 µl  template           
   
PCR Program 
     
      
         
         
 
         
Introduction of restriction sites by gradient PCR. A third PCR was performed to introduce 
restriction sites for restriction endonucleases SacII, Sal I, Kas I and BssHII (New England 
Biolabs, Germany) for the heavy and the light chain, respectively. Al reagents used for these 
PCRs were provided from NEB. The annealing temperatures for the gradient were primer- 
specific.  
 
Phusion PCR reaction (20 µl)   
 
4 µl   5X GC reaction buffer 
0.2 mM   dNTPs 
0.5 µM   forward primer 
0.5 µM   reverse primer 
0.2 µl   Phusion DNA polymerase (1.0 unit/50 µl PCR) 
20 ng   template   
0.6 µl   DMSO   
 
 
PCR program 
 
 
 
 
Rat MOG. The construct for the full length rat MOG was ordered at Eurofins MWG GmbH 
(Germany) (NCBI reference sequence: NM_022668.2). The construct was designed with 
restriction sites for the endonucleases XhoI and EcoRI and subcloned into the pEGFP-N1 
vector (CLONTECH Laboratories, Mountain View, CA). 
 
Recombinant hMOG. The construct for recombinant hMOG was ordered at Eurofins MWG 
GmbH (Germany). It contained the extracellular domain of wild type (wt) hMOG which was 
Denaturation 95ºC 15 min 
  
Denaturation 94 ºC 30 sec 
Annealing 55 ºC 30 sec 
Elongation 72 ºC 45 sec 
Elongation 72 ºC 10 min 
  
 30 cycles 
Denaturation 98ºC 30 sec 
  
Denaturation 98 ºC 15 sec 
Annealing primer specific 
Elongation 72 ºC 45 sec 
Elongation 72 ºC 10 min 
  
  35 cycles 
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connected via a flexible 11–amino acid linker GSGMGMGMGMM, from (O'Connor, 
McLaughlin et al. 2007) to a C-terminal Avi-tag sequence (GLNDIFEAQKIEWH), used for 
site-specific biotinylation, and a poly-His-tag sequence. It was digested with the restriction 
endonucleases NheI and NotI and subcloned into the pTT5 expression vector. 
2.2.1.3 Agarose gel electrophoresis 
Agarose gels were prepared by dissolving agarose powder (Biozyme, Germany) in TAE 
buffer. For visualization of DNA under UV (ʎ= 254-366 nm) SYBR Safe (Life Technologies, 
Germany) 1:10000 or ethidium bromide (1µg/ml) were added. The percentage of the gel 
depended on the size of the analyzed DNA product and ranged from 1-2 %. DNA samples 
were mixed with gel loading dye (6x) (Serva, Germany), and loaded on the gel. The size of 
the samples was determined by comparison with a molecular weight standard (peqGOLD 
50bp, Peqlab, Germany; Gene Ruler 100bp and 2-LoG-ladder, NEB, Germany). 
2.2.1.4 DNA extraction from agarose gel 
DNA fragments of interest were cut out from the gel with a scalpel and extracted by using the 
QIAquick GelExtraction Kit or the QIAquick PCR Purification Kit (Qiagen) in accordance to 
the protocol provided by the manufacturer. 
2.2.1.5 Determination of DNA quantification 
DNA was quantified by using a Nanodrop spectrophotometer (Peqlab). A blank 
measurement was done with the DNA TE buffer (Qiagen) or with water, afterwards, 1 µl of 
the DNA sample was loaded for photometric measurement at 260 nm to determine DNA 
concentration and purity. 
2.2.1.6 Restriction digest 
Restriction endonucleases cleave DNA at a specific recognition site. All restriction enzymes 
were used according to the protocol provided from the manufacturer. 1 U of enzyme 
corresponds to the amount required to cleave 1 µg of DNA in 1 hour in a total volume of 20 
µl. 
2.2.1.7 Ligation of DNA 
Ligation was performed by using the T4 DNA Ligase (NEB) and following the instructions of 
the manufacturer. 50 ng of vector and a molar ratio of 1 (vector) to 3 (insert) were used. 
Reactions were carried out for 1-3 hours at RT or overnight at 16 ºC. 
2.2.1.8 Sequence analysis of DNA 
All DNA samples were sent for sequencing to the sequencing facility of the LMU Biocenter 
(Martinsried, Germany). 
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 Microbiological methods 2.2.2
2.2.2.1 Transformation of competent bacterial cells by heat shock 
Competent E. coli DH5α or purchased NEB 5-alpha Competent E.coli (High efficiency) (NEB) 
were used for plasmid amplification. For the transformation of competent E. coli DH5α, 300  
ng of plasmid were used to transform 50 µl of thawed bacterial cells. Cells were incubated for 
20 minutes on ice and then heat-shocked for 90 seconds at 42 ºC. This was followed by a 
incubation for 5 minutes on ice. 400 µl of LB medium was added and cells were put on a 
shaker at 150 rpm for 30 minutes at 37 ºC. Afterwards, 200 µl of cells were plated on a LB-
Amp or LB-Kan agar plate and incubated overnight at 37 ºC. The rest of the bacterial culture 
was stored at 4 ºC. LB medium (for 1 L in water) consisted of: 10 g Bacto-tryptone (BD 
Biosciences, Germany), 5 g yeast extract (BD Biosciences), and 10 g NaCl (Sigma-Aldrich, 
Germany); it was brought to pH 7.5 using NaOH and sterilized by autoclaving. For LB-agar, 
15 g of agar were dissolved in 1L of LB and sterilized by autoclaving. For LB-Amp agar, 
ampicillin (Sigma-Aldrich) was added to a final concentration of 100 µg/mL, while for LB-Kan 
agar, kanamycin (Sigma- Aldrich) was added to a final concentration of 50 µg/ml. 20 mL of 
LB agar  was poured onto 10 cm culture plate (Greiner, Germany) for casting and the plates 
were stored at 4 ºC until use. The transformation of NEB 5-alpha Competent E.coli (High 
efficiency) (NEB) was performed according to the manufacturer’s protocol with the following 
modifications: 10 ng of plasmid or 3 µl of ligation product were added to 30 µl of thawed 
bacterial cells. Next steps were performed as indicated and cells were recovered by adding 
200 µl of room temperature SOC medium (Invitrogen). Cells were placed on a shaker at 250 
rpm for 30 minutes at 37 ºC and then plated on LB agar plates. 
2.2.2.2 Plasmid DNA purification from bacterial cells 
Plasmid DNA was purified from E. coli by using Miniprep, Midiprep and Maxiprep kits 
(Qiagen) and by following the protocol provided from the manufacturer. The resulting plasmid 
DNA was sent for sequence verification, used for further cloning procedures or cell 
transfection. 
 Cell biological methods 2.2.3
2.2.3.1 Cell culture of HeLa cells 
HeLa cells were cultivated in T75 cell culture flasks (BD Biosciences) at 37 °C and 10% CO2. 
Cells were passaged every 48 hours at a 1:10 ratio. In detail, cell culture medium was 
removed, cells were washed with 10 ml PBS (Invitrogen) and 2 ml Trypsin-EDTA (Invitrogen) 
were added. Cells were incubated for 5-10 minutes at 37 °C and trypsinization was 
neutralized by adding 8 ml of culture medium. 
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HeLa culture medium                Dulbecco’s modified Eagle Medium (DMEM) (Invitrogen) 
      
10 % fetal calf serum (FCS) (Gibco) 
     1 %   Penicillin/Streptomycin (Gibco) 
 
2.2.3.2 Cell culture of HEK 293 EBNA 1 cells 
HEK 293 EBNA 1 cells were cultured in suspension in an incubator (Multitron Pro) with 
humified atmosphere at 37 °C, 8 % CO2 and 110 rpm.  Cells were passaged every 48-60 
hours to a density of 200.000 cells/ml. 
HEK 293 EBNA 1 culture medium Freestyle 293 Expression medium (Gibco) 
     1 % Pluronic F-68 10 % (Gibco) 
     25 µg/ml Geneticin G418 (Gibco) 
 
2.2.3.3 Cell count and viability 
Cell count was determined by using a Neubauer improved hemocytometer (Marienfeld-
Superior). The cell suspension was diluted with 0.05 % Trypan blue solution and then the 
number of cells in four big quadrants was counted. Trypan blue is able to pass through the 
membrane of dead cells and allows therefore the determination of the number of living cells. 
The average of counted cells was multiplied by the dilution factor and by 104 in order to 
determine the number of cells/ml. 
Trypan blue solution  0.4 % Trypan blue (Sigma-Aldrich)    
    1X PBS (Invitrogen) 
2.2.3.4 Isolation of human peripheral blood mononuclear cells (PBMC) by density gradient 
centrifugation 
Fresh blood was obtained from adult healthy volunteers and from adult patients of the 
outpatient clinic of the Institute of clinical Neuroimmunology of the Klinikum Großhadern 
(Munich, Germany). The blood was collected in 9 ml EDTA tubes (Sarstedt) in order to 
prevent clotting. PBS and blood were mixed in a 1:1 ratio in a 50 ml Falcon tube (BD) and 
then transferred to a second Falcon tube containing 15 ml Pancoll (human Pancoll density 
1.077 g/l PanBiotech). Samples were centrifuged at 4 °C for 35 minutes at 400 g without 
break. After centrifugation, erythrocyte sediment on the bottom layer while plasma and 
PBMC are on the top of the Pancoll layer. Plasma was carefully removed and stored at – 20 
°C. PBMCs were transferred to a new 50 ml Falcon tube, washed by adding 20 ml of PBS 
and centrifuged at 4 °C for 10 minutes at 300 g. This process was repeated three times. 
Afterwards, cells were counted and frozen in 5x106 cell aliquots at -80 °C in freezing medium 
(FCS, 10 % DMSO). Cells were transferred to liquid nitrogen for long term storage.  
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2.2.3.5 Isolation of murine splenocytes 
Spleens from wt and transgene Th (IgHMOG) C57BL/6 mice were kindly provided by Dr. 
Kerstin Berer. Th mice were used because the BCR of their B cells carries a rearranged 
heavy chain of a MOG-specific antibody (Litzenburger, Fässler et al. 1998). To prepare a 
single cell suspension of spleen cells, the spleen was put into a cell strainer (BD) which was 
localized on the top of an empty 50 ml Falcon tube. Spleens were mashed through the 
strainer into the tube by using the plunger of a 20 ml syringe (BD). Plunger and cell strainer 
were rinsed by adding 5 ml of RPMI complete medium. This procedure was repeated three 
times. Cells were centrifuged at 400 g for 7 minutes. Supernatant was discarded and 
erythrocytes were lysed by incubating the cell pellet in 2.5 ml ACK lysing buffer for 2 minutes. 
As a next step, 45 ml of RPMI complete medium were added and the cells were centrifuged 
at 400 g for 7 minutes. The cell pellet was suspended again in RPMI complete medium. This 
procedure was repeated three times. Cells were counted, suspended in freezing medium 
(FCS, 10 %DMSO) and stored in 5x106 aliquots at -80 ºC.  
RPMI complete medium               RPMI-1640 Medium (Invitrogen) 
     10 % FCS (Gibco) 
     1 %   Penicillin/Streptomycin (Gibco) 
     1 %   Sodium Pyruvate (Gibco) 
     1 %   Non-essential Amino Acids (Gibco) 
     10 mM L-glutamine (100mM, Gibco) 
 
10x ACK lysing buffer               1.5 M NH4Cl 
     100 mM KHCO3 
     10 mM Na2EDTA 
      
2.2.3.6 Human B cell stimulation with Resiquimod and IL-2  
Naive human B cells were stimulated in order to obtain Ig-secreting cells. PBMCs from 
healthy donors or from patients were suspended in RPMI complete medium at a 
concentration of 300.000 cells/ml. Resiquimod (R848, Sigma-Aldrich) and recombinant 
human IL-2 (R&D) were added at a concentration of 2.5 µg/ml and 1000 UI/ml, respectively 
(Pinna et al, 2006). Cells were cultivated for 7 and 10 days at 37 ºC, 5 % CO2. 
 
 Isolation of human B cells 2.2.4
Human B cells were isolated from fresh PBMC by using the B-cell isolation kit (Miltenyi 
Biotec). Isolation was performed according to the instructions provided by the manufacturer.
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 Recombinant protein expression 2.2.5
2.2.5.1 Optimization of the expression of hMOG on HEK and HeLa cell 
The expression of MOG on HEK and HeLa cells was tested by using two different 
transfection reagents: Lipofectamine 2000 (Invitrogen) and FuGene (Promega). HeLa and 
HEK cells were seeded in a 96 well culture dish (BD) at a density of 0.25x106 cells/ml and 
0.35x106 cells/ml respectively. After 24 h cells were transiently transfected according to the 
instruction of the manufacturer. In detail, for the transfection with Lipofectamine 2000, 25 µl 
of Optimem transfection medium (Invitrogen) were mixed with either 100 or 200 ng DNA. In a 
second tube, the same amount of Optimem was mixed with 0.5 µl Lipofectamine 2000 (1:50 
ratio). The mixtures were incubated separately for 5 minutes, after that the Lipofectamine 
mixture was added to the DNA mixture followed by an incubation time of 20 minutes at room 
temperature (RT). The cell medium was completely removed and the transfection mixture 
was added to the cells for 2 h at 37 °C. As a next step, the transfection mixture was 
completely replaced by fresh DMEM. The transfection was also performed in the presence of 
FCS by adding the transfection mixture directly to the cell culture medium. For the 
transfection with FuGene, DMEM and FuGene were mixed in a 1:15 ratio while in a second 
tube the same amount of DMEM was mixed for 5 minutes with 100 or 200 ng of DNA. As a 
next step, the content of the two tubed were mixed, incubated for 15 min at RT and added to 
the cells. For both transfection reagents, cells were also transfected with the pEGFP N1 
vector (CLONTECH Laboratories) as a control.  
2.2.5.2 Generation of recombinant hMOG and IgG in the HEK 293 EBNA 1 cell line 
The extracellular domain of hMOG and the heavy and light chains of human IgG were 
expressed in serum free condition in suspension HEK 293 EBNA 1 cells (Durocher, Perret et 
al. 2002). Cells were adjusted for transfection to a density of 1x106 cells/ ml. 
Polyethylenimine (PEI) transfection reagent (Polypro Transfection) and DNA were added 
separately to Optipro serum free transfection reagent (Invitrogen), mixed and incubated for 
30 minutes at RT. 1 µg DNA and 2 µg PEI were used for 1 ml of cell suspension. Optipro was 
used in a volume corresponding to 1/10 of the cell suspension volume. The transfection 
mixture was added dropwise to the cell suspension. After 24 h incubation, Bacto TC 
Lactalbumin Hydrolysate (BD Biosciences) was added to a final concentration of 0.5 %. 
 
 Protein analysis 2.2.6
2.2.6.1 Purification of recombinant protein by immobilized affinity chromatography (IMAC) 
His Trap HP columns (GE Healthcare) were used to purify recombinant hMOG and 
recombinant abs from the supernatant of HEK 293 EBNA 1 cells. The proteins carry a C-
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terminal 6x His Tag which allows the binding to the nickel on the column. The culture 
supernatants were centrifuged at 400 g for 5 minutes at 4 °C, transferred to a new centrifuge 
tube and centrifuged again at 550 g for 20 minutes at 4 °C. As a next step, culture 
supernatants were filtered through a 0.22 µm filter (Merck Millipore) and concentrated at 
least threefold by using a Minimate TFF System (Pall Corporation) at a pressure of 200 kPa. 
Supernatants were dialyzed overnight at 4 °C against binding buffer (100 mM Na2HPO4, 500 
mM NaCl, 10 mM imidazole, pH 7.4). For purification, the column was equilibrated with 10 
column volumes binding buffer, then the sample was applied. Column was washed with 10 
column volumes binding buffer and then bounded protein was eluted by performing a linear 
imidazole gradient from 10 mM to 1 M imidazole. Wash and elution fraction were analyzed by 
SDS-Page, the fractions containing the purified protein were pooled and dialyzed against 
PBS overnight at 4 °C. Human MOG carrying the C-terminal Avi Tag has a size of 21.3 kDa 
while the purified IgG has a size of 150 kDa. 
2.2.6.2 Enzymatic biotinylation of hMOG 
MOG was biotinylated by using the BirA biotin ligase Kit (Avidity) according to the instruction 
of the manufacturer. The final reaction mixture was incubated overnight at 30 °C. Free biotin 
was removed by using 3 K centrifugal filters (Merck Millipore) and the sample was 
suspended in PBS (Invitrogen Life Technologies). Biotinylated hMOG was used to perform 
the affinity purification of MOG abs, to screen patient sera by ELISA and to generate hMOG 
tetramers. 
2.2.6.3 Generation of human MOG tetramers 
Biotinylated MOG and fluorescently labeled streptavidin (Jackson Immuno Research) were 
incubated in a molar ratio of 4:1. The required volume of streptavidin was divided into six 
aliquots which were added one by one to the biotinylated MOG. Each aliquot was incubated 
in the dark at RT for 15 minutes. The efficiency of the tetramer generation was tested by 
staining splenocytes from Th (IgHMOG) C57BL/6 mice (Litzenburger, Fässler et al. 1998). 
2.2.6.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) 
Gel electrophoresis was performed by using 4-12 % Bis Tris gels (Invitrogen) and a Xcell 
Mini Cell electrophoresis chamber (Invitrogen) filled with NuPAGE MOPS SDS Running 
buffer (Invitrogen Life Science Technologies). Samples were prepared by adding to 1-2 µg of 
protein NuPAGE LDS sample buffer (Invitrogen Life Science Technologies) and, if 
electrophoresis was performed under reducing conditions, NuPAGE sample reducing agent 
(Invitrogen). The samples were then incubated at 95 °C for 5 minutes and then loaded on the 
gel. Electrophoresis was carried out at 130 V for 90 minutes. 
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10x NuPAGE MOPS SDS Running buffer  250 mM Tris 
       1.92 M Glycine 
       1 %(g/V) SDS 
      
2.2.6.5 Determination of protein concentration 
Protein concentration was measured by using the Bicinchoninic acid (BCA) protein assay kit 
Pierce, Rockford, USA) according to the instructions of the manufacturer. 
2.2.6.6 Protein detection by Coomassie blue staining 
After gel electrophoresis, gels were incubated on a shaker for 15 minutes with Coomassie 
blue staining solution (0.1 % Coomassie brilliant-blue R-250, 40 % methanol, 10 % acetic 
acid) followed by incubation for 1 hour with destain solution (50 %methanol, 7 % acetic acid). 
Destain solution was changed from time to time. Gel was stored overnight in a 7 % acetic 
acid solution at RT. 
2.2.6.7 Mass spectrometry 
Bands of interest were analyzed by mass spectrometry. Bands were cut out from the gel with 
a scalpel and stored in 100 µl of water at -4 °C. Mass spectrometry analysis was performed 
at the core facility of the LMU. 
2.2.6.8 Antibody purification by protein G 
IgG from HC were purified by using a HiTrap Protein G column (GE Healthcare). Human 
plasma was centrifuged at 4000 g for 20 minutes at 4 °C and then filtered through a 45 µm 
filter (Merck Millipore). Dialysis against binding buffer (20 mM Sodium Phosphate, pH 7.4) 
was carried out at overnight at 4 °C by using a 50 k cutoff dialysis tube (SpectrumLabs, 
Germany). The column was equilibrated with 10 column volumes binding buffer, sample was 
loaded and unbounded protein was removed by washing the column again with 10 column 
volumes binding buffer. Bound IgG was eluted with elution buffer and immediately 
neutralized with 1 M Tris-Hcl pH 8.8. The eluted factions were concentrated with Amicon 
Ultra centrifugation filters (Merck Millipore) and dialyzed against PBS overnight at 4 °C. After 
testing their binding to MOG, purified abs were frozen in small aliquots at 4 °C. 
IgG elution buffer, pH 2.5, 1x    100 mM Glycine 
       150 mM NaCl 
        
2.2.6.9 Affinity purification of MOG-specific antibodies 
Biotinylated hMOG was diluted at a concentration of 1 mg/ml in solubilization buffer. A 
prepacked HiTrap Streptavidin HP column (GE Healthcare, Munich, Germany) was washed 
with 10 column volumes solubilization buffer, afterwards the protein was loaded on the 
column at a flow rate of 0.5 ml/min. Plasma samples were prepared as follows: plasma was 
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thawed and placed on a magnet stirrer. Slowly an equal amount of a saturated ammonium 
sulfate solution (4.1 M, pH 7.4) was added until the solution became cloudy. After 1 hour 
incubation at RT the antibody/ammonium sulfate solution was centrifuged at 8000 g for 30 
minutes at 4 °C. Pellets were dissolved in 30-50 ml PBS and transferred to 50 k cutoff 
dialysis tubes (SpectrumLabs). Tube was placed into PBS and dialysis was carried out at 4 
°C without stirring for the first 24 hours. Afterwards PBS was changed and dialysis was 
continued for another 48 hours at 4 °C with stirring. The dialyzed material was centrifuged at 
8000 g at 4 °C for 1 hour, filtered with a 0.45 µm filter (Merck Millipore) and diluted 1:10 in 
10x solubilization buffer. The sample was loaded on the column in rotation overnight at 4 °C 
at a flow rate of 0.5 ml/min. The column was washed again with 10 column volumes 
solubilization buffer. The next steps were carried out as described in section 2.2.6.8 
Solubilization buffer, pH 7.4, 1x 150 mM NaCl                                                            
6 mM Tris base                                                        
3 mM Tris-HCl                                                         
1 % Octyl- β-D-glucopyranoside 
 
 Patient material 2.2.7
The detection of MOG-specific abs and the recognized epitopes on MOG were performed by 
using sera from patients and healthy donors. Sera were provided by the medical staff of the 
Institute of clinical Neuroimmunology of the Klinikum Großhadern (Munich, Germany).  
Original samples were stored at -80 °C while working aliquots of 50 µl were stored at -20°C. 
PBMC and plasma were obtained from 20-500 ml volume blood after performing a density 
gradient centrifugation (described in section 2.2.3.4).  
 Immunological methods 2.2.8
2.2.8.1 Serum screening by FACS 
Autoantibodies against conformational-intact MOG were detected by performing a cell-based 
flow cytometry assay (Spadaro and Meinl 2016). HeLa cells were transiently transfected with 
full length hMOG fused C-terminally to the EGFP N1 (CLONTECH Laboratories, Mountain 
View, CA) vector or with EGFP alone (control cells).  24 hours after transfection, cells were 
plated in a 96 well FACS plate at a density of 50.000 cells/ well. Cells were pelleted by 
centrifugating them at a speed of 400 g for 5 minutes. Control and MOG-transfected cells 
were incubated with 100 µl of a 1:50 dilution of each serum and incubated for 45 minutes at 4 
°C. As a next step, cells were washed three times with 150 µl PBS/ 1 % FCS. MOG-specific 
IgG was detected with 100 µl of a 1:500 dilution of a biotin-SP-conjugated goat anti-human 
IgG (Jackson ImmunoResearch, West Grove, PA, USA). Cells were incubated for 30 minutes 
at 4 °C. After three washing steps, cells were incubated with 100 µl of a 1:2000 dilution of 
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Alexa Fluor® 647-conjugated Streptavidin (Jackson ImmunoResearch, West Grove, PA, 
USA) and incubated in the dark for 30 minutes at 4 °C. After three washes, dead cells were 
stained with 100 µl of propidium iodide (Sigma-Aldrich) diluted 1:2000 in PBS. FACS analysis 
was performed on a BD FacsVerse flow cytometer and data was analyzed with FlowJo (Tree 
Star Inc., Ashland, USA). The mAb 8-18C5 was used as a positive control at a concentration 
of 0.5 µg/ml. The same protocol was used for the determination of the recognized epitopes 
on MOG. In this case sera were incubated with different MOG mutants already available in 
our laboratory. Binding percentage was calculated as mean fluorescence intensity (MFI) 
(mutant) – MFI (EGFP only) / MFI (wt hMOG) – MFI (EGFP only) x 100% as described in 
(Mayer, Breithaupt et al. 2013). 
2.2.8.1.1  Isotyping by FACS 
The isotype of the MOG-specific autoantibodies was determined by performing the assay as 
described in section 2.2.8.1. Instead of the biotin-conjugated anti-human IgG antibody, the 
following abs were used: mouse anti-human IgG1 (Fc)-BIMA (1:500, Clone HP 6001), mouse 
anti-human IgG2 (Fc)-EIOT (1:500, Clone 31-7-4, Southern Biotech), mouse anti-human 
IgG3-BIOT (1:500, Clone HP 3050, Southern Biotech), mouse anti-human IgG4-BIOT (1:500, 
Clone HP 6025, Southern Biotech), biotin-SP-conjugated anti-human IgA (1:500, Jackson 
Immunoresearch) and allophycocyanin-labeled anti-human IgM (1:10, Clone: SA-DA4, 
eBioscience San Diego, CA). 
2.2.8.2 Serum screening by streptavidin ELISA 
Sera were also screened for reactivity against recombinant MOG by ELISA. After enzymatic 
biotinylation, hMOG was diluted in PBS at a concentration of 3 µg/ml and immobilized on a 
streptavidin coated 96 well plate (Nunc, Thermo Scientific) for 2 hours at room temperature 
on a shaker. Each well was then washed three times with 200 µl PBS/ 0.05 % Tween (PBST) 
and incubated at 4 °C overnight with 100 µl of a 1:100 dilution of each sera. After three 
washes, each well was incubated with 100 µl of a 1:5000 dilution of a horseradish peroxidase 
labeled goat anti-human IgG (Jackson Immuno Research) in the dark for 1 hour at RT on a 
shaker. After washing, 100 µl of TMB (Sigma-Aldrich) were added and the reaction was 
stopped after 7-8 minutes by using 50 µl of 1 M sulfuric acid. Optical density was measured 
with a Victor2 plate reader (Perkin Elmer Life Sciences) at 450 nm and 540 nm for plate 
background. Data was analyzed by using PrismGraphPad (La Jolla, USA). For comparison 
between streptavidin coated plates and maxisorp plates, serum was diluted 1:200 and wells 
containing BSA were used as negative control. The anti-MOG reactivity was calculated as 
follows: ΔOD (450 nm-540 nm). For sera screening sera from patients and HC were diluted 
1:100 and wells containing streptavidin without hMOG were used as negative controls. The 
anti-MOG reactivity was calculated as ΔOD (streptavidin + hMOG) – (streptavidin only).    
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2.2.8.3 Quantification of antibodies by ELISA 
The purified abs and the supernatants of stimulate B cells were quantified by human IgG and 
IgM ELISA development kit (Mabtech) according to the protocol of the manufacturer. 
Maxisorp plates (Nunc, Thermo Scientific) were coated with a MT145 antibody or a 
monoclonal anti-IgM antibody diluted to 2 µg/ml in PBS and incubated overnight at 4 °C. 
Wells were washed twice with 200 µl PBS and blocked by adding 200 µl/well of incubation 
buffer (PBS with 0.05% Tween, 0.1% BSA) for 1 hour at RT. Wells were washed five times 
with PBST and incubated for 2 hours at RT with 100 µl of serial dilutions of human IgG or 
IgM standard solutions (7.8 ng/ml to 500 ng/ml in PBS) and antibody samples. Elution and 
wash fractions were diluted 1:100 and 1:200, plasma and flow through were diluted 1:1000 
and then 1:50 and 1:100. The supernatants of not stimulated and stimulated B cells were 
diluted respectively 1:2 and 1:80. After washing, wells were incubated for 1 hour at RT with 
100 µl of MT78-ALP or anti-IgM-ALP detection antibody diluted 1:1000 in incubation buffer. 
Wells were again washed and 100 µl/well of pNPP substrate (Sigma-Aldrich) was added. 
Optical density was measured at 405 nm after suitable developing time.  
2.2.8.4 Binding activity of purified abs by FACS 
Binding of affinity purified abs to MOG was tested by performing the CBA described in 
section 2.2.8.1 with the following modifications: 50.000 HeLa cells transfected with human, 
mouse and rat MOG were incubated with 50 µl of eluted sample diluted in PBS/1 % BSA to a 
final concentration of 12 µg/ml. Plasma, wash fraction and flow through were tested at the 
same concentration. 
2.2.8.5 Binding activity of affinity purified and recombinant antibodies by ELISA 
Affinity purified and recombinant abs were also tested by ELISA. In detail, maxisorp plates 
(Nunc, Thermo Scientific) were coated overnight at 4 °C with 100 µl/well of  recombinant 
human, mouse and rat MOG diluted in coating buffer (100 mM sodium carbonate, pH 9.5) to 
a final concentration of 10 µg/ml. Each well was washed three times with 200 µl PBST (PBS 
with 0.05 % BSA) and then incubated with 100 µl blocking buffer (3 % BSA in PBS) for 2 
hours at RT. After washing three times, each well was incubated for 2 hours at RT with the 
samples diluted in incubation buffer (0.5 % BSA in PBS). Affinity purified abs were tested at a 
concentration of 6 µg/ml and 12 µg/ml while recombinant abs were serial diluted from a 
concentration of 50 µg/ml to 1 µg/ml. The next steps were carried out as described in section 
2.2.8.2. The same protocol was used to perform saturation binding experiments to determine 
antibody KD values. Affinity purified and recombinant abs were used at a concentration 
ranging from 10 to 160 nM and 6.6 nM to 8000 nM, respectively. Negative controls were 
used at the same concentrations. To determine the KD values, saturation binding data were 
analyzed with GraphPad Prism 7 using nonlinear regression analysis. 
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2.2.8.6 Western Blot 
Proteins were separated by SDS-Page and then transferred by semidry electroblotting (60 
mA, 90 minutes, Bio-Rad) onto a PVDF membrane, which was first activated in 100 % 
methanol. The membrane was blocked in 5 % skim milk in 0.05 % PBST at RT for 1 hour 
and then incubated with the abs HRP-anti-His (Sigma- Aldrich), at a dilution of 1:1000 and 
HRP-anti-human IgG (Jackson ImmunoResearch), at a dilution of 1:2500, at RT for 1 hour.  
The membrane was washed three times in 0.05 % PBST and bound HRP-conjugates were 
visualized by adding enzymatic chemiluminescence (ECL, GE Healthcare) for 1 minute. 
Visual analysis was performed with Odyssey ® CLx Imaging System (LI-COR Biosciences). 
 Single cell sorting of MOG-binding B cells  2.2.9
First, human B cells isolated from fresh PBMC were stained with PE-CD19 (BD 
Pharmingen), PE-Cy7-CD27 (eBioscience), V450-IgM (eBioscience) and APC-hMOG 
tetramer. Subsequently CD19+CD27+IgM-MOG-binding B cells were sorted as single cells 
by using a BD FACSAriaTM 2 flow cytometer. In vitro differentiated MOG-specific B cells were 
stained with PE-CD19 (BD Pharmingen), PE-Cy7-CD27 (eBioscience), V450-CD38 
(eBioscience) and a FITC-mMOG tetramer. MOG tetramers were used at a concentration 
range of 0.150 ng-1 µg/ml. Single cell sorting was performed in collaboration with Dr. Markus 
Moser at the Max Planck Institute for Biochemistry.   
 Immunohistochemistry 2.2.10
For neuropathological analysis tissues were fixed in 4 % phosphate buffered 
paraformaldehyde and routinely embedded in paraffin. Paraffin sections were stained with 
hematoxylin & eosin, Luxol fast blue myelin stain and Bielschowsky silver impregnation for 
basic neuropathological classification. Serials section were then stained by 
immunocytochemistry with antibodies against the following targets: CD3 (RM 1907S, 
Neomarkers), CD8 (M7103, DAKO), CD20 (MS 340S, Neomarkers), CD68 (MO814, DAKO), 
p22phox (sc-20781, Santa Cruz), MOG (8-18C5, gift from C. Linington, Glasgow), PLP (MCA 
839G, Serotec), CNPase (SMI91, Sternberger Monoclonals), Neurofilament (AB 1981, 
Chemikon), GFAP (Z=334, DAKO), Aquaporin 4, Aquaporin 1 (sc 20810, Santa Cruz), 
human immunoglobulin (RPM 1003, Amersham) and activated terminal complement (C9, 
C9neo, rabbit polyclonal and mouse monoclonal B7; gift from P, Morgan, Glasgow). 
Immunocytochemistry was performed with a biotin avidin peroxidase technique as described 
in (Fischer, Wimmer et al. 2013). Prof. Hans Lassmann performed the histopathological 
analysis of human biopsy tissue sections, rat brain and spinal cord and provided the 
information for this text. For binding of human affinity purified or recombinant IgG to rat MOG, 
rat brains were fixed in 4 % paraformaldehyde (PFA) for 1 hour, cryoprotected with 40 % 
sucrose for 48 hour, and snap frozen in chilled isopentane. Seven micron thick sagittal 
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sections were incubated with 0.3 % hydrogen peroxide for 20 minutes, with 10 % donkey 
serum in PBS for 1 hour, and then labeled with patient or control sample (1:200) at 4 °C 
overnight. The next day, sections were labeled with a donkey-anti-human 
secondary antibody (1:2000) for 2 hours at RT and visualized with 
an avidin-biotin-diaminobenzidine (DAB) reaction. Analysis was performed by Prof. Romana 
Höftberger who provided the information for this text. 
 
  Animal experiments 2.2.11
MOG-specific T cell lines were generated using antigen-primed donors. To induce mild EAE, 
freshly restimulated MOG-specific T cells were injected intravenously (i.v) in Lewis rats. 
Clinical scores were evaluated as follows: 0 = normal; 0.5 = loss of tail tonus; 1 =tail 
paralysis; 2 = gait disturbance; 3 = hind-limb paralysis; 4 = fore-limb paralysis; 5 = moribund. 
Two days after EAE induction, the following abs were injected intrathecally (i.t) : 90 µg of 
affinity purified patient abs and IgG from a healthy donor used as negative control, 500 µg of 
the recombinant ab r2246_D7 and the negative control AB3. The mAb 8-18C5 and the 
humanized r8-18C5 (Brändle, Obermeier et al. 2016) abs were used as positive controls, 
respectively. A mouse IgG1 antibody (eBioscience) was used as isotype control. For the 
monitoring of clinical score, animals were followed until full recovery and were then 
sacrificed. For subsequent immunohistochemical analysis, 72 hours after antibody injection, 
animals were perfused with PBS and 4 % PFA in PBS under terminal anesthesia; the spinal 
cord and brain were then postfixed with 4 % PFA in PBS at 4 °C. Animal experiments were 
performed by PD Dr. Naoto Kawakami who provided the information for this text. 
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3 Results 
Parts of the following results were published in (Spadaro, Gerdes et al. 2015, Spadaro, 
Gerdes et al. 2016).  
 Optimization of the CBA for the detection of MOG-specific abs 3.1
The first aim of this study was to optimize the CBA for the detection of MOG-specific abs 
already established in our laboratory. To this end, the transfection reagents Lipofectamine 
and FuGene and the HeLa and HEK cell lines were compared. HeLa and HEK cells were 
transiently transfected with EGFP (control cells) or MOG-EGFP by using FuGene (Figure 4A) 
and Lipofectamine 2000 (Figure 4B and C) as transfection reagents. Since transfection is 
usually performed by using serum reduced medium, for the transfection with Lipofectamine 
2000 we also tested the influence of FCS present in the cell culture medium on the 
transfection efficiency (Figure 4B and C).  
 
A  
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Figure 4: Optimization of transfection efficiency. Transfection efficiency of HeLa cells by using 
FuGene (A, upper histograms) or Lipofectamine 2000 (B) as transfection reagents and comparison 
with HEK cells (A, lower histograms and C, respectively). Transfection with Lipofectamine 2000 was 
also tested in the presence and absence of FCS in the culture medium (B for HeLa cells, upper and 
lower histograms, respectively and C for HEK cells). Numbers indicate the percentage of cells with a 
transfection efficiency >100 in the FITC channel.  
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The transfection efficiency was determined by gating on the cells showing a signal > 100 in 
the FITC channel. Cells transfected with FuGene showed an efficiency between 4.8 % and 
30 %, and 6.3 % and 3.6 % for HEK and HeLa cells, respectively (Figure 4A). As expected, 
the use of Lipofectamine 2000 in the presence of FCS induced a reduction of the transfection 
efficiency (Figure 4B for HeLa cells and 4C for HEK cells). The highest transfection efficiency 
was obtained with HeLa cells transfected with Lipofectamine 2000 in the absence of FCS 
(Figure 4B, higher histograms). Therefore, we decided to use this protocol, which is 
described in detail in section 2.2.5.1. In order to determine the presence of anti-MOG abs, 
we increased the sensitivity of the assay: we used for our analysis only cells with a 
transfection intensity >500 in the FITC channel and acquired at least 30.000 events at the 
flow cytometer. The murine anti-MOG mAb 8-18C5 was used as a positive control (Figure 5). 
 
 
 
Figure 5: Gating strategies and validation with the 8-18C5 mAb. HeLa cells transfected with EGFP 
or hMOG-EGFP were incubated with the anti-MOG mAb 8-18C5. We gated on HeLa cells (upper plot, 
left) and excluded from our analysis the dead cells (upper dot, right). To quantify the anti-MOG 
reactivity, we set the gates on the cells expressing high levels of EGFP or hMOG-EGFP (dashed 
rectangle) and calculated the FACS ratio as MFI (MOG-EGFP)/ MFI (EGFP only). 
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 Occurrence of abs against conformation-intact hMOG in adult 3.2
patients             
We used our CBA to screen sera from a total of 260 patients: NMOSD (n=18), ON (n=14), 
MS (n=104 including: RRMS n=94, SPMS n=4 and CIS n=6), encephalomyelitis (n=8), 
autoinflammatory syndromes (n=61) and with other forms of encephalomyelitis (n=55). 
Patients with non-inflammatory neurological diseases (NIND, n=45) and HC (n=39) were 
used as controls (Figure 6). The threshold for anti-MOG reactivity was set to the mean plus 3 
SD of n=39 adult HC (Figure 6), which resulted in a FACS ratio of 2.27. The experiments 
were performed according to the protocol described in section 2.2.8.1. We found anti-MOG 
reactivity in a total of 17/260 (6.5%) patients, these included: 4/18 NMOSD patients, 4/14 ON 
patients, 5/94 RRMS patients and 4/8 patients with encephalomyelitis. None of the patients 
diagnosed with SPMS or CIS tested positive for anti-MOG abs. 53 % of the anti-MOG abs 
positive patients were female and 47 % male. The age at the time point of first sample 
collection was between 23 and 66 years. One patient with NMOSD (serum ID 2347), one 
with relapsing encephalomyelitis (serum ID 2144) and two HC showed a reactivity which was 
at the detection limit (FACS ratio 2.4 and 3.0, respectively). Also one patient of the NIND 
control group tested positive (FACS ratio 3.98). As shown in Table 6, patients with the 
highest anti-MOG reactivity were diagnosed with unilateral or bilateral ON, these patients 
showed in our CBA a FACS ratio ≥ 15 (Mean FACS ratio 67.08). 3 of the 17 patients who 
tested positive for anti-MOG abs, were also diagnosed with an autoinflammatory syndrome: 
two with familial mediterranean fever (FMF) and one patient with cryopyrin-associated 
autoinflammatory syndrome (CAPS). 
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Figure 6: Anti-MOG reactivity by flow cytometry. Serum screening by FACS using hMOG included 
samples from patients with NMOSD (n=18), ON (n=14), MS (n=104), encephalomyelitis (n=8) and 
autoinflammatory syndromes (n=64). The dotted line indicates the cutoff for anti-MOG reactivity (2.27). 
Values for each anti-MOG IgG-positive patient represent the mean of ≥ 2 independent measurements. 
The three patients with anti-MOG abs and an autoinflammatory syndrome are indicated with the 
orange (serum ID 2215), blue (serum ID 1771) and green (serum ID 0211) symbols twice.  
Therefore, in order to determine whether MOG-specific abs also occur in patients with these 
diseases, we screened additional 61 sera from patients with autoinflammatory diseases, 
none of them tested positive. 
Table 6: Characteristics of patients with abs to MOG 
 
*
n ≥ 2 independent measurements. AZA: Azathioprine, RX: Rituximab, NAT: Natalizumab, IFN: 
interferon,  FMF: familial Mediterranean fever, CAPS: cryopyrin-associated inflammatory syndrome. 
 
  Isotyping of MOG-specific abs 3.2.1
Sera containing anti-MOG abs, were further analyzed to determine the Ig subclasses IgG1-
IgG4 and the IgM and IgA classes by using the procedures described in section 2.2.8.1. We 
identified the presence of the complement-activating IgG1 subclass in 8/17 patients (Figure 
7). The full-length humanized r8-18C5 mAb (Brändle, Obermeier et al. 2016) was used as a 
positive control. This antibody contains the human IgG1- and ĸ- constant regions. The 
observation that we could not determine the IgG isotype in all 17 anti-MOG antibody positive 
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patients is in line with the fact that the polyclonal goat anti-human IgG secondary antibody 
that we used for serum screening is much more sensitive than the IgG subclass secondary 
abs. One NMOSD patient (serum ID 1771) tested also positive for anti-MOG IgM (see 
section 3.6.1 for additional details). None of the patients had anti-MOG abs belonging to the 
IgG2-4 subclasses or the IgA class.  
 
Figure 7: Isotype of MOG-specific abs. The abs responsible for anti-MOG reactivity were isotyped 
by flow cytometry (right). The humanized r8-18C5 mAb was used as a positive control (left). Anti-MOG 
reactivity was determined by the incubation of a 1:50 dilution of the sera with EGFP transfected control 
cells (closed gray graphs, shown here for one patient as an example) and hMOG-EGFP transfected 
cells (coloured lines). Sera were diluted 1:50, the r8-18C5 antibody was used at a 0.5 µg/ml 
concentration.  
 
 Epitope mapping on conformation-intact MOG 3.2.2
The 17 sera with anti-MOG abs were also analyzed for epitope specificity. Six variants of 
human MOG were previously generated in our laboratory and used to investigate the 
antibody binding in a cohort of 111 pediatric patient sera (Mayer, Breithaupt et al. 2013). 
These constructs carry a C-terminal intracellular EGFP tag and include the not glycosylated 
variant of hMOG (N31D) and the mutants R9G/H10Y, P42S, R86Q, S104E and 
H103A/S104E. The amino acids that were exchanged in these constructs are localized at 
different loops of the protein (Figure 8A): P42 is localized on the CC’ loop, H103 and S104 
on the FG’ loop, R9 and H10 at the AA’ loop and R86 at the EF’ loop. The transfection of 
HeLa cells with the different mutants showed a comparable efficiency (Mayer, Breithaupt et 
al. 2013), this allowed us to use them for the analysis and comparison of antibody binding. 
We used as positive controls the mouse mAb Z2 and the humanized r8-18C5. The 
humanized r8-18C5 antibody offered the advantage to use the same detection system as for 
human samples. Previous studies showed that different murine MOG-specific mAbs 
recognize different epitopes (Breithaupt, Schäfer et al. 2008, Mayer, Breithaupt et al. 2013): 
while the 8-18C5 antibody does not bind to the MOG variants containing the S104E 
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mutation, the Y11 antibody recognizes all MOG variants. We observed that the Z2 antibody 
has the same epitope pattern as the 8-18C5 antibody (Figure 8B). 
 
 
Figure 8: Epitope mapping on conformational-intact hMOG. Sequence conservation of mMOG 
and hMOG mapped onto the three-dimensional structure of mMOG: Cα-atoms of residues that were 
mutated are shown as largest spheres: R9G/H10Y in red and blue, N31D greenish, H103A/S104E in 
gray, and P42S and R86Q in purple. Cα-atoms of nonconserved residues, which were not mutated are 
shown as midsited spheres: G59A/D60E, D74E/A75T and G77S. These Cα-atoms are highlighted in 
blue, indicating coservative amino acid differences between mMOG and hMOG. Cα-atoms of non 
conserved residues with side chains located inside the protein are shown as small spheres: V20A and 
F98Y. Figure taken from (Mayer, Breithaupt et al. 2013), Copyright 2013, The American Association of 
Immunologists, Inc.(A); HeLa cells transfected with hMOG variants, mouse and ratMOG were 
incubated with a 0.5 µg/ml concentration of the r8-18C5 or Z2 abs. Values obtained with wt hMOG 
were set at 100% and the other reactivities were calculated as described in section 4.2.2 (B); example 
of anti-MOG response directed against one epitope in one ON patient (serum ID 2816):  binding to 
mutant P42S and to mMOG is >90% reduced (C); example of anti-MOG response directed against 
multiple epitopes in one encephalomyelitis patient (serum ID 2144): binding to mutants R9G/H10Y and 
H103A/S104E is reduced of a 50% while binding to mMOG is absent (D). Depicted are the mean 
values of ≥ 2 independent experiments ± SEM. 
In 40 % of our anti-MOG-IgG positive patients, the antibody binding was directed against 
only one single epitope. These patients included three of four ON patients, three of four 
NMOSD patients and two of five RRMS patients. The autoantibodies in the remaining 60 % 
showed a reactivity directed against multiple epitopes: one ON patient, one NMOSD patient, 
three RRMS patients and three encephalomyelitis patients had a reactivity which was 
directed against two different epitopes (either against loops FG’ and CC’, loops AA’ and FG’ 
or loops CC’ and EF’) (Figure 9A). The fourth patient with encephalomyelitis was the only 
one who showed an anti-MOG reactivity against three different epitopes (CC’, AA’ and FG’ 
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loops) and will be described in detail in section 3.3. 13 of 17 patients showed a higher 
reactivity to the not glycosylated variant of MOG (N31D), one patient recognized this mutant 
at least as good as wt hMOG while the remaining three patients showed a lower binding 
(Figure 9B). In two of these three patients binding to the not glycosylated MOG was reduced 
to 50 % compared to wt hMOG while in the third patient the decreased binding was not 
significant. We observed a more than 2-fold higher reactivity also against other mutated 
variants of MOG: one encephalomyelitis patient showed an increased binding to the single 
mutant S104E and the double mutant H103A/S104E; one ON patient had a 6.4-fold higher 
reactivity against the P42S variant and a 5-fold higher reactivity against mouse MOG 
(mMOG). This patient will be described in more detail in section 3.6.1. 
 
 
Figure 9: Recognized epitopes by anti-MOG abs positive patients. Anti-MOG response directed 
against the different loops on MOG (A); Binding percentage against the mutant N31D compared to the 
binding percentage against wild type hMOG (set to 100 %). Binding percentage was calculated as 
described in section 2.2.8.1. Depicted are the mean values of n=3 independent experiments ± SEM. 
 
 Recombinant expression of rat MOG and binding of human sera 3.2.3
One aim of this study was to investigate the pathogenicity of human MOG-specific abs in 
animal models. Since these animal experiments were planned to be performed in an EAE 
model in the Lewis rat, we analyzed specifically also the cross-reactivity to rat MOG. A 
previous study in our laboratory with pediatric samples showed that only a minority of 
patients has MOG-specific abs that recognize rodent MOG (Mayer, Breithaupt et al. 2013). In 
order to determine in this study if sera from adult patients are reactive against mouse and rat 
MOG, HeLa cells were transiently transfected, according to the protocol described in section 
2.2.8.1, with full length rat or mouse MOG-EGFP and the transfection efficiency was 
compared to that of hMOG-EGFP (Figure 10A). Surface expression and correct folding of rat 
MOG was evaluated with the mAbs 8-18C5 and Z2 (Figure 10B). Of the 17 sera that tested 
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positive for anti-hMOG reactivity, three (serum ID 1771, 2246 and 3202) showed also strong 
binding to rat MOG (Figure 10C). In these three sera we observed to rat MOG a mean FACS 
ratio of 53.8 ± 8.8 SEM compared to the mean FACS ratio of 1.6 ± 0.3 SEM observed in sera 
without anti-rat MOG abs. FACS ratio was calculated as described in section 2.2.8.1. 
 
A  
B  
   C  
Figure 10: Reactivity to conformational-intact rat MOG. HeLa cells were transiently transfected 
with EGFP (control) and rat MOG-EGFP. Transfection efficiency was calculated by gating on cells with 
an EGFP signal >500 (A, left and middle); comparison of the transfection efficiency with hMOG and 
mMOG (A, right).Transfected HeLa cells were incubated with a concentration of 0.5µg/ml of the mAbs 
Z2 and r8-18C5 (B). Transfected HeLa cells were incubated with a 1:50 dilution of each serum. The 
MFI in the APC-channel was used to determine antibody binding and FACS ratio was calculated as 
previously described. Shown is one representative histogram of n ≥ 2 independent measurements. 
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  Histopathology and clinical course of MOG-associated 3.3
encephalomyelitis 
Among the four encephalomyelitis patients who showed anti-MOG reactivity in our CBA, we 
focused our attention on a 66-years old Caucasian woman (serum ID 1819). The clinical 
phenotype of this patient is summarized in Table 7. The performance of a brain biopsy, 
carried out to exclude a progressive multifocal leukoencephalopathy, allowed us to describe 
the histopathology. 
Table 7: Clinical features in a patient with MOG-associated encephalomyelitis                             
(index patient 1819). 
 
LETM: long extensive transverse myelitis. 
 
  Abs to MOG in index patient 1819 3.3.1
The anti-MOG abs of index patient 1819 had the complement-activating IgG1 isotype at 
months 19 (data not shown) and 32 (Figure 11A) after disease onset. There was no evidence 
for intrathecal production of MOG-specific abs (Figure 11B). We identified amino acids on 
MOG (R9/H10, P42, S104) as critical for antibody binding and noted that the not glycosylated 
MOG was recognized better than wt hMOG (Figure 11C-D). No cross-reactivity to murine 
MOG was observed (Figure 11C). This is consistent with the fact that mouse and rat MOG 
contain the mutant amino acids G9/Y10 and S42. The pattern of epitope recognition stayed 
constant over time (Figure 11D). We performed longitudinal analysis of anti-MOG response 
for an observation time of 24 months (Figure 11E): the anti-MOG reactivity increased until 
month 32 after disease onset, when the biopsy was performed, and subsequently dropped 
as a consequence of immunoadsorbance (IA).  
 
 
Similiarities Differences
MS MS type II histopathology no oligoclonal bands
relapsing-remitting disease course no typical periventricular  lesions  
 
NMOSD brainstem and spinal cord 
involvement
no LETM
large lesio  in the splenium no optic nerve involvement
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A  
B   
C   D      
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Figure 11: Clinical course and antibodies to MOG in index patient 1819. The isotype of the MOG-
specific abs was analyzed by using the serum sample obtained 32 months after disease onset (A). For 
the analysis of intrathecal production of abs to MOG, serum and CSF were adjusted to the same IgG 
concentration and incubated with EGFP control cells (grey) and hMOG transfected cells (black line) 
(B); Reactivity to MOG variants after 19 (black) and 32 (gray) months after disease onset. Sera were 
diluted 1:50 and incubated with different MOG mutants. Binding percentage was calculated as 
described in section 2.2.8.1 (C). Visualization of amino acids recognized by the patient’s 
autoantibodies (this figure was prepared by Prof. C. Breithaupt). The structure of the hMOG model is 
shown as Cα-trace. Cα-atoms of the frot β-sheet are colored blue, those of the back β-sheet green. 
The amino acids involved in antibody binding are shown as stick models. Cα-Cα and minimum side 
chain distances are given in Å (D). Figures taken from (Spadaro, Gerdes et al. 2015).  The dashed 
horizontal line indicates the threshold of anti-MOG positivity. This figure was prepared in collaboration 
with Dr. Lisa Ann Gerdes (E). Mean ± SEM of three replicates. AZA: Azathioprine, MMF: 
mycophenolat mofetil; RX: Rituximab; IA: immune adsorption; EDSS: expanded disability status scale. 
  Neuropathological examination 3.3.2
During the observation period of three years, the patient’s lesions spread in a caudo-cranial 
direction, starting with multifocal spinal cord lesions, followed by brainstem involvement and 
subsequently by a large bihemispheric white matter lesion which showed regression over 
time (Figure 12). The appearance of this large lesion corresponded to month 32 after disease 
onset. At this time point a brain biopsy was performed and histological analysis was carried 
out from our coworkers from the Center for Brain research in Vienna. 
 
Figure 12: Cerebral MRI of index patient 1819. Cerebral MRI D1 and D2, 32 months after disease 
onset: the arrows indicate a bihemispheric, sharply demarcated confluent tumefactive parieto-occipital 
lesion across the splenium of the corpus callosum with rim-enhancing pattern; regression of large 
bihemispheric lesion in the splenium of the corpus callosum and lack of Gd-enhancement 47 months 
after disease onset. Scale bars, 50 µm. Modified from (Spadaro, Gerdes et al. 2015). 
Histopathological analysis revealed an inflammatory demyelinating lesion with partial axonal 
preservation and reactive astrocytic scaring (Figure 13). Inflammation was reflected by T-
lymphocytes and activated macrophages or microglia. Areas of active demyelination were 
characterized by profound reactivity for C9neo indicating terminal complement activation, 
and accumulation of IgG. These were not observed in the normal appearing white matter or 
in the inactive lesion core (Figure 13) and were the main features of the histological defined 
MS pattern II (Lucchinetti, Brück et al. 2000). In the lesion center, numerous CNPase-
positive premyelinating oligodendrocytes were present, but fully remyelinated lesion areas 
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were not contained within the biopsy specimen. Astrocytes showed changes of 
protoplasmatic and fibrillary gliosis without loss of AQP-4 or-1 reactivity. Neurofilament 
staining showed preservation of axons in the demyelinated lesion (Figure 13).  
 
Figure 13: Histopathological analysis of index patient 1819. (A) Moderate tissue infiltration by 
CD8
+
 T lymphocytes. (B) activated macrophages, expressing the p22 component of the NADPH 
oxidase complex. (C) macrophages contain luxol fast blue-positive myelin degradation products. (D) 
loss of MOG immunoreactivity at the active site of the lesion; MOG-positive granules can be seen in 
the cytoplasm of macrophages (early active lesion). (E) more intense immunoreactivity for PLP; PLP is 
also seen in granular form in the cytoplasm of macrophages. (F) the most intense immunoreactivity for 
myelin-related proteins is seen for CNPase;(H) immunoreactivity for activated complement (C9neo 
antigen) is only present at the active lesion edge, but not in the normal appearing white matter (G), or 
the inactive lesion center (I). (H) At the active lesion edge C9neo reactivity is seen on myelinated 
fibers and inmyelin degradation products within macrophages. In the lesion center complete 
demyelination is seen; (J) immunocytochemistry for CNPase shows numerous immunoreactive cells 
(premyelinating oligodendrocytes) and a fine meshwork of CNPase reactive fibers; (K) astrocytes 
within the lesion are preserved, show reactive gliosis as seen by GFAP staining and (L) express 
aquaporin 4; (M) immunocytochemistry for phosphorylated neurofilament shows preservation of axons 
in the demyelinated lesion; (N)sections stained for amyloid precursor protein reveal a moderate 
number of axons with disturbed fast axons transport. (O,serial section to H) Staining for human 
immunoglobulin G shows profound accumulation of IgG in early active lesions; IgG is diffusely 
deposited in the lesions, but shows accentuation on fibrillar structures in a similar pattern as depicted 
for complement C9neo staining. Magnification bars: 50 µm. CNPase, cyclic nucleotide 
phosphodiesterase; PLP, proteolipid protein (B). This figure was taken from (Spadaro, Gerdes et al. 
2015). 
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 Abs to MOG in a distinct subgroup of adult multiple sclerosis 3.4
Abs to MOG were found in 5/104 patients (Figure 6) who fulfilled the diagnostic criteria for 
MS and were preselected for a specific clinical phenotype (severe spinal cord, optic nerve 
and brainstem involvement). Since we identified a patient with biopsy proven MS pattern II 
(described in section 3.3) we investigated two additional cohorts for the presence of anti-
MOG IgG: n=22 biopsied patients with demyelinating diseases of the CNS (n=19 with RRMS 
and n=3 with ADEM), four of whom classified as MS type II, and n=55 sex and age-matched, 
otherwise unselected MS patients (see table 8 for clinical characteristics of the three groups). 
None of the patients of these two additional groups tested positive for anti-MOG reactivity 
(Figure 14A). The intensity of anti-MOG reactivity in these patients was similar to what we 
observed in the patient with MOG-associated encephalomyelitis. The availability of follow up 
samples allowed us to perform in these five MS patients the anti-MOG a longitudinal analysis 
of the anti-MOG response with a mean observation period of 7 years. In three of these 
patients, we noted intermittent disappearance and reappearance of the anti-MOG response 
(Figure 14B). This was particularly striking in patient 558 in whom a strong anti-MOG 
response transiently disappeared and then reappeared 7 years later at a similar intensity 
(Figure 14C). 
Table 8: Clinical characteristics of patient groups 1-3 
 
 
 
 
 
 
 
 
 
 
 
 
MSSS=multiple sclerosis severity scale. This table was taken from (Spadaro, Gerdes et al. 2016) and 
prepared by Dr. Lisa Ann Gerdes. 
  Sex 
(f/m) 
Age 
years, 
mean 
(range) 
Diagnosis 
Disease 
duration, 
years, 
mean 
(range) 
EDSS, 
mean 
(range) 
MSSS, 
mean 
(range) 
Details 
Group 
1, 
n=104 
65/39 37 
(19-62) 
RRMS=94 
SPMS=4 
CIS=6 
8 (0-31) 
  
3.7           
(1-8.5) 
5.97  
(0.56-
9.74) 
severe/recurrent ON 
n=50, 48% (n=14 
bilateral ON); 
brainstem n=56, 54%; 
severe/recurrent 
myelitis n=61, 59%; 
severe spinal cord 
involvement n=18, 17% 
PLEX performed n=38 
response to PLEX n=28 
Group 
2, 
n=55 
30/25 39 (18-
70) 
RRMS=53 
SPMS=2 8 (0-31) 
2.5 (0-
6.5) 
3.92             
(0.35-
9.63) 
age/sex matched, 
otherwise unselected 
multiple sclerosis 
patients 
Group 
3, 
n=22 
18/4 45 (25-
73) 
RRMS=11, 
SPMS=2, 
CIS=6, 
ADEM=3 
5.9         
(0-28.7) 
3.27       
(1-9.5) 
5.42    
(0.74-
9.99) 
brain biopsy 
classification: Type I=4, 
Type II=4, Type III=3, 
no classification 
possible=11 
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The anti-MOG response in this patient showed the same epitope specificity 9 and 16 years 
after disease onset (Figure 14D). 
A B  
C D  
Figure 14: Anti-MOG reactivity in adult MS. Sera from three groups of patients with MS were 
analyzed for anti-MOG reactivity. Group 1: patients with MS with a specific clinical phenotype (severe 
or recurrent myelitis and/or severe or recurrent optic neuritis, and/or brainstem syndrome) (n=5/104). 
Group 2: unselected patients with MS matched for age and sex (n=55). Group 3: biopsied patients 
(n=22), 4 with MS type II pathology (empty triangles). The dashed line indicates the cutoff for anti-
MOG positivity (2.27). Values shown for each anti-MOG IgG–positive patient represent the mean of 3 
independent measurements using the first serum sample analyzed, which was 14, 16, 3, 18, and 9 
years after disease onset for patients 1 through 5 (A). Clinical features, therapies, and longitudinal 
analysis of abs to MOG in two MS patients,corresponding to sera 0211 and 558 in table 7.
(B,C). Analysis of the epitope specificity of the MOG 
reactivity of the samples indicated with asterisks in C. Mean ± SEM of three independent replicates. 
DMF = dimethyl fumarate; DMT = disease-modifying therapy; EDSS = Expanded Disability Status 
Scale; FTY = fingolimod; GLAT = glatiramer acetate; IVIG = IV immunoglobulins; MFI = mean 
fluorescence intensity; NAT = natalizumab; PLEX = plasma exchange; RX = rituximab. Figures 
modified from (Spadaro, Gerdes et al. (2016). 
 
 Clinical phenotype of anti-MOG IgG positive patients with MS 3.4.1
Clinical information of the analyzed patients was provided by PD Dr. Tania Kümpfel and Dr. 
Lisa Ann Gerdes.  All five patients with MS had a typical RRMS with several relapses over 
time, typical CSF findings with presence of OCBs, and MS-typical cerebral MRI features from 
the beginning of the disease. When we compared the clinical features of the five anti-MOG–
positive patients with MS to anti-MOG–negative patients of group 1, we noted that four 
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patients with abs to MOG had concomitant severe spinal cord and brainstem involvement, 
while this combination was seen in only 7 of 99 patients without abs to MOG. A combination 
of all three specific clinical characteristics (severe/recurrent ON, severe/recurrent myelitis, 
and brainstem syndrome) was observed in three of five patients with abs to MOG and in 3 of 
99 patients without abs to MOG (Table 9). All five patients with MS who had MOG-specific 
abs showed an active disease course as indicated by high relapse rates and therapy failure 
to several disease modifying therapies (DMTs) (Table 9). Severe relapses at the beginning of 
MS led to Expanded Disability Status Scale (EDSS) scores 4.0 in four patients early on. 
Three of the five patients with abs to MOG responded favorably to plasma exchange (PLEX) 
therapy (Table 9). Serum samples from MOG antibody–positive patients were not available 
from disease onset; however, we could analyze the anti-MOG response longitudinally in all 
five patients with a mean observation period of seven years (Figure 15). 
Table 9: Clinical characteristics of anti-MOG positive patients compared to anti-MOG negative 
patients in selected MS patients (group 1) 
 
Table modified from (Spadaro, Gerdes et al. 2016). 
 
The anti-MOG reactivity fluctuated over time and only partially correlated with clinical disease 
activity. In patients 0211 and 558, anti-MOG reactivity reappeared during episodes of clinical 
and/or radiologic disease activity (Figure 15). Patient 2703 tested positive for MOG-specific 
abs during a severe brainstem and ON relapse, but tested negative seven and eight years 
later during a phase of clinical stabilization while under natalizumab therapy (Figure 15A). 
Patient 2169 could be tested only twice during a time interval of two years and showed 
ongoing disease activity accompanied by positive anti-MOG reactivity at both time points 
(Figure 15B). Patient 467 had a stable disease course. In this patient abs to MOG fluctuated 
during continuous natalizumab treatment (Figure 15C). 
Clinical 
characteristics
Anti-MOG abs + 
(n=5)
Anti-MOG abs - 
(n= 99)
severe/recurrent ON 4 of 5 50 of 99
brainstem syndrome 4 of 5 53 of 99
severe/recurrent 
myelitis
5 of 5 56 of 99
severe myelitis and 
brainstem syndrome
4 of 5 7 of 99
severe ON and 
myelitis and 
brainstem syndrome
3 of 5 9 of 99
response to PLEX 3 of 3 25 of 35
DMT ≥3 4 of 5 21 of 99
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Figure 15: Longitudinal analysis of MOG-specific abs and clinical score. MS Patients 2703 (A), 
2169 (B) and 467 (C). Figures modified from (Spadaro, Gerdes et al. 2016). 
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 Detection of MOG-specific abs by ELISA 3.5
MOG-specific abs were also tested by ELISA. In this method, the antigen is adsorbed on a 
solid support. The use of streptavidin coated plates and of biotinylated hMOG as coating 
antigen, allowed us to increase the sensitivity compared to the ELISA performed with 
maxisorp plates (Figure 16A). Moreover, the presence of a flexible linker between the 
extracellular domain of MOG and the biotinylation site (see section 2.2.6.2) offers the 
advantage that epitopes on MOG are more accessible for antibody binding (Figure 16B). For 
comparison between streptavidin coated plates and maxisorp plates, sera 1771 was diluted 
1:200, the mAb 8-18C5 was used at 0.5 µg/ml. 
A  
               B    
 
Figure 16: ELISA optimization by using biotinylated hMOG as coating antigen. Reactivity of the 
8-18C5 mAb and human serum 1771 against hMOG or BSA (used as a negative control) is shown 
here. The streptavidin plate was coated with 3 µg/ml of biotinylated hMOG (left), while the maxisorp 
plate was coated with 10 µg/ml of hMOG (right). ELISA reactivity is shown here as OD (450 nm-540 
nm). Serum was used at a 1:200 dilution, the 8-18C5 mAb was used at a 0.5 µg/ml concentration. 
Mean ± SD, n ≥ 2 (A); the construct used for the streptavidin ELISA contains the extracellular domain 
(ED) of hMOG (in grey). The flexible linker between this part of hMOG and the biotinylation site (Avi 
Tag) is depicted in green. The violet line represents the Igĸ leader sequence (B).  
Wells were coated for serum screening with biotinylated hMOG at a 3 µg/ml concentration. 
Wells containing only streptavidin were used as a negative control. We tested by ELISA 116 
patients and 87 HC (Figure 17A). The patient cohort included the 17 patients which showed 
anti-MOG reactivity by FACS and 89 RRMS, 6 CIS and 4 SPMS patients. All the patient 
samples were also tested in the CBA. 
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A     
             B          
Figure 17: Reactivity to MOG by ELISA. Screening of 116 patients and 87 HC by ELISA. Biotinylated 
hMOG was added to streptavidin coated plates. The anti-MOG reactivity is expressed as ΔOD 
(streptavidin + hMOG) – (streptavidin only). See section 2.2.8.2 for more details. Open circles 
represent sera that scored positive by FACS, red circle corresponds to the human serum used daily 
control. The dashed line represents the cutoff value which was calculated as mean of the anti-MOG 
reactivity (ΔOD) of the HC+3SDs (A). Correlation between the anti-MOG reactivity (MFI ratio) 
measured by FACS and the anti-MOG reactivity (ΔOD) measured by ELISA. Sera indicated by the 
arrows were the only ones that showed high reactivity in both assays, these patient sera were affinity-
purified. Numbers indicate patient sera that tested positive by FACS (B).  
7/116 patients (6%) showed by ELISA anti-MOG reactivity above or close the cutoff value 
(1.02): 5 of these patients (open circles) tested also positive in our CBA (three ON patients, 
one NMOSD patient and one patient with relapsing encephalomyelitis), the other two positive 
patient samples were diagnosed with RRMS and were negative in our CBA. The anti-MOG 
reactivity observed by FACS and ELISA was congruent for the two sera 1771 and 2246, 
these showed the highest reactivity against conformationally intact MOG (Table 6). Overall, 
we did not observe a correlation between the results obtained by FACS and ELISA (Figure 
17B, Spearmen r=0.16, p = 0.07). Also 1 of 87 HC (2016-18) tested positive by ELISA but 
not by FACS. Our results show that the ELISA with a display of MOG with a site directed 
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biotinylation at the C-terminus is more sensitive than the ELISA with a conventional binding 
of MOG to a maxisorp plate.  
 Affinity purified anti-MOG abs from patients 1771 and 2246 3.6
Among the analyzed patient sera, those from two patients (1771 and 2246) were the only 
ones who showed anti-MOG reactivity by FACS and ELISA and cross-reactivity to rat MOG. 
Therefore, MOG-specific abs from these patients were affinity purified in order to perform an 
in vivo analysis of their pathogenic potential. The detailed analysis of these serum samples 
and the establishment and validation of the affinity purification are described in the next 
sections. 
 Detailed analysis of patient sera 1771 and 2246 3.6.1
Patient 1771, a 46 years old female, was diagnosed with relapsing bilateral ON and with 
CAPS, a rare, inherited autoinflammatory disease. We performed a longitudinal analysis of 
the anti-MOG reactivity for an observation time of 26 months, during that period the patient 
did not obtain any treatment and the disease course was stable. The anti-MOG abs were of 
the IgG1 isotype and the IgM class, we did not observe any significant fluctuation of the anti-
MOG response during the observation time (Figure 18A). Reactivity due to MOG-specific abs 
of the IgG class was observed up to a dilution of 1:12150 at which the MFI ratio was 6.2 
(Figure 18B). Since the anti-MOG abs were planned to be used for transfer experiment in 
Lewis rat and since rat and mouse MOG show differences in their amino acid sequence 
(Breithaupt, Schäfer et al. 2008), we tested also the reactivity to rat MOG and observed a 
strong binding (Figure 18C ): the binding percentage of MOG-specific IgG and IgM for rat 
MOG was 19 % ± 0.38 and 15.5 % ± 0.98, respectively. We could detect also an anti-MOG 
reactivity in the CSF, however, we did not observe an intrathecal production of anti-MOG IgG 
since the MFI ratio of the CSF (72.44) was lower than the MFI ratio of the corresponding 
serum (86.34) adjusted to the same IgG concentration (Figure 18D). Abs of the IgG and the 
IgM classes showed a similar reactivity to the different mutant variants of MOG.  (Figure 
18E): anti-MOG reactivity was directed against P42, localized in the CC’ loop on MOG.  
Patient 2246, a 49 years old male, was diagnosed with a severe relapsing unilateral ON and 
showed a stable disease course during an observation time of 35 months. Two months after 
the first sample collection, a therapy with the immunosuppressive drug Azathioprine (AZA) 
was started. The analysis of the second follow-up sample showed a strong reduction of the 
anti-MOG reactivity, which remained stable for the rest of the observation period (Figure 
19A). Anti-MOG reactivity could be detected up to a serum dilution of 1:12150, MFI ratio was 
3.53 (Figure 19B). 
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Figure 18: Detailed analysis of the anti-MOG reactivity in patient 1771 by FACS: for longitudinal 
analysis, sera of the different time points were diluted 1:50 and incubated with HeLa cells transfected 
with EGFP (control cell) or hMOG-EGFP. Anti-MOG reactivity was detected by using as secondary 
anti-human IgG (green line) or anti-human IgM (blue line). MFI ratio was calculated as follows: MFI 
(MOG-EGFP)/MFI (EGFP). Green and blue dashed lines represent the corresponding cutoff value 
(2.27 for IgG and 2.96 for IgM) (A). Sera from the first time point was diluted from 1:50 up to 1:109350 
dilution and analyzed for anti-MOG IgG (B). IgG and IgM Abs were also tested for binding to rat MOG 
(C). Serum and CSF of the first time point were adjusted to the same IgG concentration (22 µg/ml) and 
tested for anti-MOG reactivity. The MFI ratio of the CSF was 72.44, while that of the serum sample 
was 86.34 (D). Comparison of the recognized epitopes on MOG by MOG-specific IgG and IgM: HeLa 
cells transfected with different variants of hMOG or with mMOG were incubated with a 1:50 dilution of 
the sera and MOG-reactivity due to abs of the IgG or the IgM class was analyzed. Mean ±SEM, n=2 
(E).  
Sera from this patient showed a high reactivity against rat MOG (MFI ratio was 141.4) 
(Figure 19C). MOG-specific abs had the IgG1 subclass (Figure 19D). The analysis of the 
reactivity against different MOG epitopes revealed that the anti-MOG response in this patient 
was directed against H103 of the FG’loop and R9 and H10 of the AA’ loop. Moreover, we 
observed a stronger binding to the P42S mutant than to the wt MOG (Figure 19E). 
 Establishment and validation of affinity purification of MOG-specific abs 3.6.2
For the establishment of an affinity purification protocol we first tried to use NHS columns 
with covalently conjugated hMOG. The mAb 8-18C5 was used as a positive control and the 
eluted antibody was tested by FACS for binding to conformationally intact hMOG expressed 
on the surface of HeLa cells (Figure 20, upper histograms). Importantly, while the mAb 8-
18C5 was completely absorbed by this column, the anti-MOG Abs from the patient 1771 
were largely unbound as seen by high anti-MOG reactivity in the flow through. 
Results 
 
51 
 
 
Figure 19: Detailed analysis of the anti-MOG reactivity in patient 2246 by FACS: for longitudinal 
analysis, sera of the different time points were diluted 1:50 and incubated with HeLa cells transfected 
with EGFP (control cell) or MOG-EGFP. Anti-MOG reactivity was detected by using as secondary anti-
human IgG (green line). MFI ratio was calculated as follows: MFI (MOG-EGFP)/ MFI (EGFP). Green 
dashed line represents the corresponding cutoff value (2.27) (A). Serum from the first time point was 
diluted from 1:50 up to 1:109350 dilution and analyzed for anti-MOG reactivity (B). Abs were also 
tested for binding to ratMOG (C). MOG-specific abs were of the IgG1 subclass (D). Analysis of the 
recognized epitopes on MOG: HeLa cells transfected with different variants of hMOG or with mMOG 
were incubated with a 1:50 dilution of the sera and MOG-reactivity due to abs of the IgG class was 
analyzed. Mean ± SEM, n=3 (E). 
Only a very small amount (1.2 µg) of anti-MOG could be recovered after loading of 20 ml 
plasma on this column. Both the eluted fractions of the 8-18C5 antibody and of the patient 
sample 1771 showed anti-MOG reactivity (Figure 20, lower histograms). As an alternative 
approach, we biotinylated hMOG at the Avi-Tag linked to the C-terminus and bound the 
protein to streptavidin sepharose columns. EDTA blood from patients 1771 and 2246 was 
collected at different time points during the observation period and corresponded to a total 
plasma volume of 600 ml and 1200 ml, respectively. More details about the amount of 
unpurified and purified abs are provided in table 10. Eluted abs were separated by SDS-
Page and visualized by Coomassie blue staining, bands of interest were cut out and 
analyzed by mass spectrometry (Figure 21). We could identify by mass spectrometry in the 
eluted sample from patient 2246 abs of the IgG class, while the eluted sample from patient 
1771 contained both abs of the IgG and the IgM class. 
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Figure 20: Binding of the eluted fractions of the 8-18C5 mAb and patient 1771 to native hMOG. 
HeLa cells were transiently transfected with EGFP (control) or hMOG-EGFP and incubated with the 
starting material (loaded sample and unpurified plasma, respectively), eluted abs and the flow through. 
All samples were adjusted to a concentration of 12 µg/ml. All fractions tested in the CBA were purified 
by using an NHS column loaded with hMOG. 
This is consistent with our CBA results, which showed that among the identified anti-MOG 
positive patients, patient 1771 was the only one who, apart from anti-MOG IgG, had also 
anti-MOG abs from the IgM class (Figure 21). 
 
Figure 21: Elution fractions of material from ON patients 1771 and 2246 purified by using 
biotinlyated hMOG. Eluted abs were dialyzed against PBS and 21 µl of each fraction was analyzed 
using SDS-Page and Coomassie blue staining under reducing and not reducing conditions. The bands 
in the red boxes were cut out and analyzed by mass spectrometry. 
Both preparations showed also lower amounts of albumin, fibrinogen and α-2 macroglobin. 
The eluted fractions were quantified by IgG and IgM ELISA (see section 2.2.8.3 for detailed 
protocol) and the enrichment of MOG-specific abs in the eluted fractions was analyzed by 
FACS and ELISA. 
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Table 10: IgG and IgM concentration of unpurified plasma and purified fractions 
 
 
  Validation of affinity purification by FACS and ELISA 3.6.3
For FACS analysis, HeLa cells were transfected as usual with EGFP and hMOG-EGFP and 
incubated with unpurified plasma material or purified abs adjusted to the same antibody 
concentration (12 µg/ml; 600 ng/50.000 cells) (Figure 22A).  
 
 
Figure 22: Binding analysis of affinity purified MOG-specific abs by FACS and ELISA. Unpurified 
plasma and purified abs from patients 1771 and 2246 were tested for reactivity to full length hMOG-
Sample ID Gender Diagnosis Therapy
Amount of Abs in the 
unpurified sample (mg) Amount of purified Abs (µg)
1771 female Relapsing bilateral ON and CAPS no IgG: 1339 IgM: 23.45 IgG: 471.4 IgM: 54.66
2246 male Relapsing unilateral ON AZA IgG: 1500 IgG: 571.2
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EGFP (black and red line) at a concentration of 12µg/ml. EGFP cells (in grey) were used as a control. 
Abs from the HC Donor 1 were used as a negative control (A).Unpurified plasma and purified abs 
were tested by ELISA for reactivity against recombinant hMOG; the r8-18C5 mAb and IgG from HC 
Donor 1 were used as positive and negative control, respectively. Unpurified material, purified abs and 
HC IgG were adjusted to a concentration of 6µg/ml, the r8-18C5 mAb was used at 0.5µg/ml (B).Error 
bars represent SDs and asterisks represent significance based on Student’s t test as compared with 
the unpurified fraction (** p˂ 0.005; *** p˂0.0005; **** p˂0.0001). 
The eluted fraction of both patients showed an enrichment of MOG-specific abs by FACS: 
the FACS ratio of the purified abs was 12.7 and 17.6 times higher than the FACS ratio of the 
unpurified material, respectively in patient 1771 and 2246. Both antibody preparations 
showed also by ELISA a significantly higher reactivity compared to the unpurified fraction 
(Figure 22B). We quantified by ELISA the binding of the affinity purified abs to recombinant 
hMOG and calculated the dissociation constant (KD) which was 7 nM for the IgG purified from 
patient 1771 and 45.95 nM for the IgG purified from patient 2246. The KD of the positive 
control mAb 8-18C5 was 2.4 nM (Figure 23A).The affinity purified abs recognized also the 
not glycosylated MOG variant (Figure 23B).  
 
 
Figure 23: Binding features of affinity purified abs by ELISA. Saturation experiments were 
performed by ELISA to determine the affinities of the purified abs from patients 1771 and 2246 for 
recombinant hMOG. The 8-18C5 mAb and the IgG from HC Donor 1 were used as positive and 
negative control, respectively. n=3. Error bars represent SDs. (A). Binding to the unglycosylated MOG 
variant by ELISA. n=2. Error bars represent SDs. (B)  
Affinity purified abs from patient 2246 were obtained in a higher yield and where therefore 
also used for indirect immunohistochemistry experiments on rat brains: we observed a strong 
labeling on myelin in the cerebral and cerebellar white matter whereas control IgG remained 
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negative (Figure 24). This staining was carried out by our collaboration partner Prof. Romana 
Höftberger of the Medical University of Vienna. 
 
 
Figure 24: Indirect immunohistochemistry of affinity purified abs from patient 2246 on non-
perfused rat brain. IgG from a MOG-negative patient with a psychiatric disorder was used as 
negative control (picture prepared from Prof. Romana Höftberger). Staining of the cerebral and 
cerebellar area are shown in detail in the middle and lower figure, respectively. Affinity purified abs 
and negative control were used at a concentration of 3 µg/ml. 
 
 Pathogenicity of affinity purified abs against MOG 3.6.4
Affinity purified abs from patients 2246 and 1771 were used to investigate their potential 
pathogenicity by in vivo experiments performed in Lewis rats (see section 2.2.11 for detailed 
protocol). These abs were analyzed for reactivity against mMOG and rat MOG in FACS 
(Figure 25A) and ELISA (Figure 25B). For the transfer experiments, EAE was induced in 
Lewis rats by the injection of MOG-specific T cells (T MOG-GFPn).  Two days after EAE 
induction, affinity purified MOG specific IgG from patients 1771 and 2246, the mAb 8-18C5 
and total IgG from HC Donor 1 were injected intrathecally. 
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Figure 25: Binding analysis of affinity purified MOG-specific abs to mMOG and rat MOG by 
FACS and ELISA. Binding of purified abs to HeLa cells transfected with full length mMOG-EGFP and 
ratMOG-EGFP. HeLa cells transfected with EGFP only (in grey) were used as a control. Abs were 
used at a concentration of 12 µg/ml (A); Reactivity by ELISA of unpurified plasma and purified abs 
against mMOG and rat MOG. Unpurified material and purified abs were adjusted to a concentration of 
6 µg/ml. n=2. Error bars represent SDs and asterisks represent significance based on Student’s t test 
as compared with the unpurified fraction (** p˂ 0.005; *** p˂0.0005; **** p˂0.0001) (B).  
Both the mAb 8-18C5 and the abs from patients 1771 and 2246 induced an increase of 
disease severity and a significant weight loss, while the negative control did not show any 
effect (Figure 26). Rats treated with the abs obtained from patients 1771 and 2246 showed 
five days after EAE induction a clinical score of 2.25 ± 1.06 and of 1.75 ± 0.35 SD, 
respectively.  Rats treated with the mAb 8-18C5 had at the same time point a clinical score of 
2.75 ± 1.06 SD. The animals were sacrificed 72 hours after antibody injection and brains and 
spinal cords were prepared for immunohistochemical analysis. Animal experiments were 
performed in cooperation with Dr. Naoto Kawakami. 
 Histopathological analysis 3.6.5
Pathological analysis of the spinal cord revealed in animals treated with the patient’s abs or 
with the mAb 8-18C5 inflammation reflected by the massive subpial infiltration of CD3+T-
lymphocytes. This was absent in the animals treated with the abs from HC Donor 1 (Figure 
25 A-C). 
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Figure 26: Clinical score and weight loss in Lewis rats treated with patient derived MOG-
specific abs. EAE was induced in n=8 female Lewis rats by the intravenous injection of 8x10
6 
MOG-
specific T cells. Two days after injection of the MOG-specific T cells, 90 µg of each antibody were 
injected intrathecally. Abs from patients 1771 and 2246 are indicated by the red and green line, 
respectively, the mAb 8-18C5 by the black line and the negative control HC Donor 1 by the dashed 
line. Rats were scored daily for disease severity and weight change. Values = mean ± SD (2 animals 
per antibody). 
Also activated macrophages, visualized by ED1 staining, were observed in the subpial area 
in rats treated with the anti-MOG abs, this was less pronounced in the animals treated with 
control abs where macrophages were found in the perimeningeal area (Figure 27D-F). Luxol 
fast blue staining (LFB) of the spinal cord and the optic nerve showed in animals treated with 
the patient’s abs and the 8-18C5 antibody a mild perivascular demyelination, which was not 
observed in the animals treated with the control abs (Figure 27G-I). Reactivity for C9neo 
suggesting terminal complement activation was observed in the perivascular area in animals 
treated with the mAb 8-18C5 and to a lower extend in the animals treated with the patient’s 
abs, whereas it was minimal in the control animals (Figure 27J-L). Subpial deposition of 
human IgG was observed only in rats treated with the patient’s abs (Figure 27M-O). 
 Recombinant abs from patient 2246  3.7
To obtain MOG-specific B cells from patient 2246, two different approaches were used: first, 
B cells were activated and differentiated to Ig-secreting cells in vitro, tested for anti-MOG 
reactivity, and then sorted with a MOG-tetramer; second, MOG-specific B cells were directly 
sorted ex vivo. 
 MOG-specific B cells identified after in vitro stimulation  3.7.1
We used cryopreserved PBMC and induced differentiation of B cells to Ig-secreting cells by 
adding TLR7+8 ligand R848 and IL-2 (Pinna, Corti et al. 2009). B cell subpopulations were 
identified as follows: memory B cells (CD19+, CD27+, CD38-); plasmablasts (CD19+, CD27+, 
CD38+); naïve B cells (CD19+, CD27-, CD38-). MOG-specific B cells were identified by 
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staining with a FITC-labeled mMOG tetramer and belonged mainly to the memory B cell 
subpopulation (5.68% compared to 0.22% of the HC) (Figure 28A). 
 
Figure 27: Histopathological analysis of inflammation, demyelination and complement 
activation. Tissue infiltration by CD3+ T-lymphocytes (A and C), absent in B. ED1 staining of 
activated macrophages in subpial area (D and F), less pronounced macrophage deposition in E. 
Perivascular Luxol fast blue (LFB) staining in G and I, absent in H. Immunoreactivity for activated 
complement (C9neo antigen) in the perivascular area (L) and to a lower extend in J and K. Staining for 
human IgG (M), absent in N and O. 
In parallel to these tetramer stainings, the supernatants (SN) of the in vitro stimulated cells 
were analyzed for abs to MOG in our CBA (Figure 28B and C). We could detect abs that 
recognize full length hMOG and mMOG in the SN of the patient’s cells, while the SN of the 
HC did not show any anti-MOG reactivity. The stimulated cells of the other wells were 
cryopreserved and used later for single cell sorting (Figure 28D) using the murine MOG 
tetramer (kindly provided by Dr. G. Krishnamoorthy).  
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Figure 28: Phenotype of MOG-specific B cells in patient 2246. CD19
+ 
B cells of the stimulated 
wells were divided into subpopulations (naive B cells (N), memory B cells (M) and plasmablasts (PB)), 
based on the expression of CD27 and CD38 (A). M:CD19
+
,CD27
+
,CD38
-
; PB: CD19
+
, CD27
+
, CD38
+
; 
N: CD19
+ 
CD27
-
). Cells shown here were stimulated for 7 days (A). Detection of MOG-specific abs in 
the SN of stimulated B cells from patient 2246 and HC Donor 2. HeLa cells were transfected with 
EGFP, hMOG-EGFP and mMOG-EGFP and then incubated with undiluted SN to test for anti-MOG 
IgG by flow cytometry. Cells were stimulated for 7 (left plot) and 10 days (right plot). Shown is one 
representative well /conditions (B) and a summary of all tested wells (C). Gating strategy for single cell 
sorting of in vitro stimulated PBMC from patient 2246: memory B cells (CD19
+
, CD27
+
) stained by the 
mouse MOG tetramer were sorted. Stimulated cells from HC Donor 2 were used as negative control. 
Frequencies represent tetramer-positive B cells among memory B cells (CD19
+
, CD27
+
) (C). 
MOG tetramer-positive B cells of patient 2246 represented 2.94 % of CD19+ CD27+ B cells. 
The cells displayed in 28D were single cell sorted. From one of them we generated a H2L2- 
chain pair which was used to obtain full length recombinant abs. 
 Validation of human MOG tetramers and staining of PBMC ex vivo 3.7.2
The extracellular domain of hMOG was produced recombinantly in HEK 293 EBNA 1 cells, 
enzymatically biotinylated at the Avi-tag and then incubated with fluorescently labeled 
streptavidin in order to generate a tetramer. The BCR-binding activity of this tetramer was 
validated with splenocytes from MOG-Ig knock-in mice (Litzenburger, Fässler et al. 1998). 
APC and FITC labeled tetramers were compared. The APC-labeled tetramers showed a 
more efficient staining of splenocytes from IgHMOG knock-in mice than the FITC labeled 
tetramers (Figure 29A) and were therefore used for the staining of PBMC from patients with 
MOG-specific abs. These included patients with a low (patient 467) and high (patients 1771 
and 2246) anti-MOG reactivity in the CBA (Figure 29B). We identified MOG-positive B cells 
(CD19+) in patient 2246 and a weak staining of cells from patient 467 and 1771. However, we 
observed also a labelling of few B cells in a control donor who tested negative for anti-MOG 
reactivity in our CBA (Figure 29B). We optimized the staining by using negatively selected B 
cells instead of whole PBMC and gated on class-switched memory B cells. This allowed us 
to reduce the unspecific binding in HC cells (Figure 29C). This gating strategy was used for 
single sorting of freshly isolated B cells from patient 2246 (Figure 29D). MOG tetramer-
binding B cells represented 0.51 % of class-switched memory B cells. The cells displayed in 
29C were single cell sorted. From four of them we could generate H2L2- chain pairs which 
were used to obtain full length recombinant abs. 
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Figure 29: Validation of hMOG tetramers and staining of PBMC ex vivo. The extracellular part of 
hMOG was expressed in HEK 293 EBNA 1 cells, biotinylated enzymatically and allowed to form a 
tetramer with streptavidin-APC or streptavidin-FITC conjugate. MOG-tetramers were incubated with 
splenocytes from IgH
MOG
 knock-in (Litzenburger, Fässler et al. 1998) and control mice (A). Staining of 
PBMC from patients 467, 1771 and 2246 and HC with an anti-CD19 antibody and APC-labeled hMOG 
tetramer (B). Optimized staining of class-switched memory B cells (CD19
+
, CD27
+
, IgM
-
) with APC-
labeled human MOG tetramer (n=2) (C). Gating strategy for single cell sorting of fresh isolated B cells 
from patient 2246. Freshly isolated B cells from HC were used as negative control. Frequencies 
represent tetramer-positive B cells among class-switched memory B cells (CD19
+
,CD27
+
, IgM
-
) (C, 
left). 
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 Recombinant expression of IgG from patient 2246 3.7.3
We obtained from the single cell sorting of MOG-specific B cells from patient 2246 five 
recombinant IgG clones: one from the in vitro stimulated PBMC (r2246_D7) and four from the 
ex vivo isolated B cells (r2246_ E6, r2246_E3, r2246_A2 and r2246_F6). Single cell PCR 
and recombinant antibody expression are described in detail in sections 2.2.1 and 2.2.6. The 
amount of purified antibody/volume of cell suspension was variable and ranged from 0.25 – 
5.4 µg/ml. The five isolated MOG-specific B cells were not clonally related since they had 
different VH-D-JH and VK-JK gene rearrangements (Table 11). 
Table 11: Alignment of CDR3 protein sequences and VH-D-JH and VK-JK gene segment use   
 
Eluted fractions were pooled and visualized by Coomassie blue staining and Western blot 
(Figure 30). 
 
 
Figure 30: Visualization of recombinant abs by Coomassie staining and Western blot. Eluted 
fractions of recombinant abs were analyzed by Coomassie blue staining (upper figures) and Western 
Blot (lower figures). 1 µg of each antibody was loaded on the gel under not reducing (Not red) and 
reducing (Red) conditions. Western blot was performed by using an HRP-anti-His antibody. 
 
Antibody ID V-D-J Junction V D J V-J Junction V J
2246_D7 CARHPLGSGDPGDYAWDS…………… WG V4-39 D4-17 J4 CQQYYSNPYT…………… FG V4-1 J2
2246_E6 CASHRDDVWSGYSNYYHYGLDV…….. WG V3-11 D3-3 J4 CQQSHSFPLT…………… FG V1-39 J4
2246_E3 CASYVVGPTFDLSDY…………………... WG V1-2 D1-26 J4 CQHRSNWPPFT….….…. FG V3-11 J3
2246_A2 CASETWNRGILRPGP……………..…… WG V4-61 D5-12 J5 CQHYGGSPSFT…………. FG V3-20 J3
2246_F6 CARDIPAAGLFLDF……………………… WG V3-7 D6-13 J4 CQRYNTYSRDLT……...... FG V1-5 J4
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 Functional analysis of recombinant abs from patient 2246 3.7.4
Recombinant abs were analyzed for anti-MOG reactivity by ELISA and flow cytometry. Four 
of these five abs showed by ELISA reactivity against recombinant hMOG. The binding was 
quantified by calculating the binding constant (KD) (Figure 31 and Table 12). 
Figure 31: Binding of hMOG by abs generated from MOG-specific B cells. Saturation binding 
experiments were performed to determine the affinity of recombinant abs to human MOG. KD values 
are shown in Table 13.The humanized r8-18C5 mAb was used as positive control. n ≥ 2, error bars 
represent SDs. 
We probed these abs also for binding to other glycoproteins present in the CNS (NF155, 
NF186 and OmgP) generated in the same HEK 293 expression system as MOG (data 
summarized in Table 12). The r2246_E6 antibody was the only one which did not show 
reactivity to the other antigens, this was however accompanied by a low binding affinity to 
MOG (704.6 nM) (Table 12). 
Table 12: Reactivity of recombinant abs and binding quantification against hMOG  
.  
None of the generated abs showed by flow cytometry reactivity against full length human and 
murine MOG (Figure 32, data shown for r2246_D7). 
Antibody ID reactivity (ELISA) reactivity (FACS) kD (hMOG)
r2246_D7 MOG; NF155 / 277.6 nM
r2246_E6 MOG / 704.6 nM
r2246_E3 / / /
r2246_A2 MOG; omgP; NF155; NF186 / 28.4   nM
r2246_F6 MOG: NF155;NF186 / 385    nM
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Figure 32: Binding of r2246_D7 to full length MOG by FACS. HeLa cells were transfected with full 
length hMOG-EGFP and mMOG-EGFP. Antibody was used at a concentration of 1 µg/ml and 50 
µg/ml. HeLa cells transfected with EGFP only were used as control cells. 
 Transfer of human recombinant abs in Lewis rats 3.7.5
In order to determine the potential pathogenicity of the human recombinant abs described 
above, we performed in vivo experiments in Lewis rats. The recombinant antibody used for 
these experiments was r2246_D7 since it showed both higher affinity to MOG and less 
binding to the tested antigens compared to the other recombinant abs. Mild EAE was 
induced by intravenous injection of 8x106 MOG-specific T cells (T MOG-GFPn). Two days 
after EAE induction, 500 µg of the r2246_D7 antibody were injected intrathecally. The murine 
8-18C5 mAb and the humanized r8-18C5 antibody were used as positive controls, while the 
rAb3 and a commercial mouse IgG1 antibody were used as negative controls. Both the 
murine 8-18C5 mAb as the humanized r8-18C5 antibody induced an increase of disease 
severity, while the human r2246_D7 antibody did not show any effect (Figure 32). Rats 
treated with the positive controls showed four days after EAE induction an increase of the 
clinical score, reaching at day five a maximum value of 2.5 for the murine mAb 8-18C5, and 
then completely recovered at day nine.  
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Figure 32: Clinical score in Lewis rats treated with recombinant MOG-specific abs. EAE was 
induced in n=2 male Lewis rats by the intravenous injection of 8x10
6
 MOG-specific T cells. Two days 
after EAE induction, 500 µg of each antibody were injected intravenously. Isotype control (IC), the 
humanized r8-18C5 antibody and the murine 8-18C5 mAb are indicated by the black, the blue and the 
green lines, respectively (left). The r2246_D7 and the negative control Ab3 are indicated by the full 
and empty circle symbol, respectively (right). Rats were scored daily for disease severity and weight 
change (not shown).  
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4 Discussion 
 Clinical spectrum of patients with abs to MOG  4.1
In this study, 17 sera from adult patients from the Institute of Clinical Neuroimmunology 
showed reactivity against conformation-intact MOG. In adults, abs to MOG have been 
described in several autoimmune disorders with partly overlapping features (Figure 33): they 
occur in a subset of AQP4-antibody negative NMO patients and patients with ON but are 
absent in most patients with classical adult MS. We here show, to our knowledge for the first 
time, that abs to MOG can occur also in adult patients with classical RRMS and clinical 
features reminiscent of NMOSD.                                                                                                      
 
Figure 33: Overlapping features of MOG-antibody-associated CNS disorders. Abs to MOG are 
detected in a proportion of patients with different clinically defined CNS diseases: MS (childhood MS, 
especially before puberty and classic adult MS with a NMOSD-like phenotype), NMOSD, bilateral ON, 
ADEM and anti-NMDA-receptor (NMDAR)-antibody-associated encephalitis. Some patients with abs 
against MOG have clinical features that overlap with different autoimmune disorders, but fall outside 
current classification schemes. Modified from (Hohlfeld, Dornmair et al. 2016).  
We observed the highest reactivity against MOG in patients diagnosed with ON and 
NMOSD. Our findings confirm previous studies which describe the presence of abs to MOG 
in proportions of patients with ON and anti-AQP4 abs negative NMOSD (Mader, Gredler et 
al. 2011, Kitley, Woodhall et al. 2012, Ramanathan, Reddel et al. 2014) 
Among our cohort of patients with abs to MOG, three were also diagnosed with an 
autoinflammatory disease. These include two patients with FMF and one patient with CAPS. 
However, there was no anti-MOG reactivity when we analyzed a larger group of patients with 
similar diagnosis. Classically, autoinflammatory diseases were considered of being unrelated 
to autoantigen-specific T cells and B cells (Masters, Simon et al. 2009, Guler, Kaptanoglu et 
al. 2012, Onur, Aral et al. 2013) . However, there is evidence that the NLRP3 inflammasome, 
which is hyperactivated in CAPS patients, is also involved in humoral immunity (Kumar, 
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Kumagai et al. 2009).  Further studies have to clarify whether there is an association 
between autoinfammatory diseases and the appearance of autoantibodies to MOG.  
Two of the HC analyzed in our study had reactivity to MOG close to the cutoff value. Abs 
against conformation-intact MOG in HC have been described previously (Lalive, Menge et al. 
2006). However, animal experiments have shown that abs to MOG are not pathogenic on 
their own, but perform a second hit, when the integrity of the blood-brain barrier is 
compromised by an already ongoing inflammatory process (Linington and Lassmann 1987, 
Schluesener, Sobel et al. 1987, Litzenburger, Fässler et al. 1998). 
Abs to MOG are more likely to be present during the early phases of childhood MS and are 
rather rare in adult MS. The first part of this study allowed us to make in this context two 
important observations: first, abs to MOG can occur in single patients with 
neuropathologically defined MS pattern II and a relapsing-remitting disease course; second, 
abs to MOG can also been found in a subset of adult patients who fulfill the McDonalds 
criteria for MS and have clinical features of NMOSD. These patients will be described in 
more detail in the next sections.  
The clinical and pathological features of index patient 1819 are different from previously 
reported anti-MOG positive cases (Kitley, Waters et al. 2014, Sato, Callegaro et al. 2014, 
Titulaer, Hoftberger et al. 2014). More in detail, the disease in this patient was different from 
NMOSD because it did not reveal any optic nerve involvement and recurrent myelitis affected 
less than two vertebral segments (no LETM). On the other hand, despite a relapsing-
remitting disease course, it could not be classified as typical MS because no OCB and no 
MS periventricular lesions were observed in this patient. Longitudinal analysis of anti-MOG 
reactivity revealed an association with the clinical course. Therefore, MOG-specific abs may 
serve as a biomarker with therapeutic implications. We observed an intense increase in anti-
MOG reactivity after initiation of therapy with rituximab (32 months after disease onset). The 
observation that the recognized epitope pattern remained stable over time supports the idea 
that this increase is due to preexisting MOG-specific antibody secreting cells and memory B 
cells, and not to epitope spreading. The mechanisms of this increase in anti-MOG reactivity 
is not clear, but a previous study performed in NMO patients showed that rituximab therapy 
resulted in an increase of the B-cell survival factor BAFF (Pellkofer, Krumbholz et al. 2011). 
Interestingly, a transient increase in abs to AQP4 was previously observed in some patients 
after rituximab therapy and was linked to elevated BAFF levels (Nakashima, Takahashi et al. 
2011).  At the time point of increase of anti-MOG reactivity the patient developed a massive, 
bilateral, parieto-occipital white matter lesion and a brain biopsy was performed (results of 
histopathological analysis will be discussed in detail in section 4.2).   
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In this study, five adult MS patients tested positive for anti-MOG reactivity. These patients 
fulfilled the diagnostic criteria for MS because they had typical MS lesions on cranial MRI, 
positive OCBs in the CSF and a typical relapsing-remitting MS disease course. Clinically they 
were characterized by severe myelitis and/or ON. It has already been postulated that some 
patients with abs to MOG may represent a subgroup of opticospinal MS (Zamvil and Slavin 
2015), this hypothesis is supported by our findings but also expanded by the fact that our 
patients had otherwise rather typical MS. Longitudinal analysis of anti-MOG reactivity for an 
observation time up to nine years, showed that abs to MOG tend to fluctuate over time and 
intermittently fell below our detection limit (2.27). The high relapse rates and lack of 
satisfactory response to several DMTs in these five patients, strongly suggest that patients 
with MS who have abs to MOG may be at higher risk to develop progressive disease and 
need escalating therapies. It is difficult to estimate the occurrence of abs to MOG in adult 
MS: our data suggests that it may range between 5 % (in a selected cohort with specific 
clinical features, like group one in this study) and less than 1% in unselected MS groups. 
One limitation of our study is the relatively small number of anti-MOG-positive patients 
diagnosed with MS, but it is still the largest and best-defined cohort of anti-MOG-positive 
adult MS described so far. In addition, since no serum sample from the time of clinical onset 
was available, we do not know whether the production of abs to MOG is a primary or 
secondary event. Previous studies in pediatric patients identified MOG-specific abs at the 
first demyelinating event, arguing therefore for a primary event in these patients (Brilot, Dale 
et al. 2009, Probstel, Dornmair et al. 2011). On the other hand, recent animal studies showed 
that an autoimmune reaction to MOG can occur upon a toxic oligodendrocyte death (Traka, 
Podojil et al. 2016). 
 
 Histopathology of anti-MOG encephalomyelitis  4.2
Histopathological analysis of the brain biopsy performed in index patient 1819 revealed 
severe demyelination with features defined previously as  “pattern II MS” (Lucchinetti, Brück 
et al. 2000). This is distinct from the astrocytopathy described in NMO (Misu, Höftberger et 
al. 2013). The lesions observed in this patient had a zonal configuration on MRI, this 
supports the findings of the histopathological examination, such as the centrifugal expansion 
reflected by densely packed macrophages at the lesion edge and the preservation of 
CNPase-positive, premyelinating oligodendrocytes within the lesion edge and center. The 
sites of ongoing demyelination at the early active lesion part showed deposition of IgG and 
activated complement. Moreover, complement activation was restricted to the area of active 
demyelination. This was unexpected, since blood-brain barrier damage with leakage of 
serum proteins was also seen in the periplaque white matter and within the lesion center.  
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The detailed analysis of antibody binding showed that not glycosylated MOG is much better 
recognized than glycosylated MOG. Presumably, glycosylation is reduced at the site of active 
inflammation facilitating as a consequence binding of abs to MOG on myelin sheaths 
resulting in complement activation. The deposition of IgG and the activation of complement 
observed in this patient are typical of MS pattern II. The presence of abs to MOG in patients 
with these neuropathological features is an important issue: the fact that among a total of five 
analyzed patients with pattern II MS, we could identify only one with abs to MOG indicates 
that MS type II in itself might be heterogeneous and is possibly associated with abs against 
different antigens. However, our findings and two recently published reports (Di Pauli, 
Hoftberger et al. 2015, Jarius, Metz et al. 2016), indicate that at least a subgroup of MS type 
II might be associated with abs to MOG.  
Our study with different groups of patients diagnosed with MS showed that many patients 
with clinical MS and MS histopathology type II do not have abs to MOG (Spadaro, Gerdes et 
al. 2015, Spadaro, Gerdes et al. 2016). These observations confirm findings from other 
studies (Jarius, Metz et al. 2016). Thus, for these patients the actual target of the pathogenic 
autoantibody response remains to be identified. 
 
  Features of abs to MOG  4.3
Our CBA allowed us to determine the IgG subclass in 8 of 17 patients: all had the 
complement activating isotype IgG1 and are therefore potentially pathogenic. Also previous 
studies revealed the IgG1 subtype to be the dominant isotype of MOG-specific abs 
(McLaughlin, Chitnis et al. 2009). Patient 1771 showed in addition also an anti-MOG 
response mediated by abs of the IgM class. IgM abs can activate the complement system 
and some of them might be pathogenic as observed in IgM monoclonal gammopathy 
associated neuropathies (Mata, Borsini et al. 2011). IgM recognizing conformation-intact 
MOG have been observed in children during a first episode of demyelination (Brilot, Dale et 
al. 2009). Patient 1771 tested positive for anti-MOG IgM for the whole observation period. 
Patients who produce IgM during an active IgG response against the same antigen have also 
been observed in previous studies (Suwannalai, Willemze et al. 2011, Filippidou, Krashias et 
al. 2016), but the exact mechanism behind that is not clear. However, the fact that the anti-
MOG IgG and IgM of our patient showed the same epitope specificity suggests that these 
anti-MOG IgM are not the result of the triggering of naïve B cells, but are mainly produced 
upon antigen stimulation (Murphy, Travers et al. 2009). The CSF of patient 1771 was 
negative for OCB and showed an anti-MOG reactivity which was lower than the response 
observed in the serum, when serum and CSF were tested at equal IgG concentrations. 
Discussion 
 
70 
These data suggest mainly a peripheral production of abs to MOG and are in line with 
previous findings (Dale, Tantsis et al. 2014, Ramanathan, Reddel et al. 2014). 
The MOG-specific abs of the adult patients analyzed in this study recognized in an equal 
proportion one single epitope and multiple epitopes on MOG. Intriguingly, patients with ON or 
NMOSD were more likely to recognize only one epitope, while the majority of MS patients 
and all encephalomyelitis patients recognized multiple epitopes. The analysis of the epitopes 
involved in antibody binding showed interindividual heterogeneity, confirming thereby 
previous findings (Mayer, Breithaupt et al. 2013). Abs of patient 1819 showed an epitope 
recognition pattern which has not yet been observed so far: three different loops are involved 
in this patient’s antibody binding to MOG. The nearly complete loss of binding to the MOG 
mutants R9G/H10Y and S104E indicated that both regions are bound simultaneously, 
consistent with the distance between amino acids and the observed maximum dimensions of 
single epitopes of up to 21 x 28 Å (Ramaraj, Angel et al. 2012). 
Binding of abs to different mutants of conformation-intact MOG were analyzed previously in 
pediatric patients, however these abs were not suitable for the investigation of their 
pathogenic potential in animal models due to low reactivity to murine MOG (Mayer, 
Breithaupt et al. 2013). Transfer experiments have been performed  with human sera and 
whole IgG from adult patients , however, the exact epitopes involved in binding to MOG were 
not known (Zhou, Srivastava et al. 2006, Saadoun, Waters et al. 2014, Flach, Litke et al. 
2016, Kinzel, Lehmann-Horn et al. 2016). To our knowledge no transfer experiments 
employing affinity purified patient-derived MOG-specific abs with known epitope recognition 
pattern have been performed so far. On the other hand, epitopes on MOG recognized by 
murine abs are known: the mAbs 8-18C5  and Z2, which were used in animal models for the 
investigation of a pathogenic role of abs to MOG, bind to MOG via the FG’ loop (Breithaupt, 
Schäfer et al. 2008). In addition, also other parts of the surface of MOG which do not belong 
to the FG’ loop are recognized by pathogenic murine mAbs (Piddlesden, Lassmann et al. 
1993). 
The extracellular domain of human and murine MOG have a > 95% sequence identity 
(Mayer, Breithaupt et al. 2013). The main differences concern R9, P42 and R86, substituted 
in murine MOG by G9, S42 and Q86, respectively. Additionally, amino acid residue H10 is 
substituted by a tyrosine residue in mMOG but not in rat MOG (Breithaupt, Schäfer et al. 
2008). Most of the patients analyzed previously did not recognize murine MOG because their 
antibody response to MOG was directed against P42 (Mayer, Breithaupt et al. 2013). In this 
study we observed that 3 ON patients (3202, 1771 and 2246) with abs to MOG showed high 
reactivity to murine MOG: in two of them this reactivity was present despite the binding to 
P42, probably explained by the recognition of Q86. Patient 2246 recognizes the MOG mutant 
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P42S much stronger than hMOG. In addition, binding to murine MOG in this patient is also 
mediated by H103, similarly to the pathogenic mAb 8-18C5 and Z2. Since H103 is conserved 
among species (Breithaupt, Schäfer et al. 2008), this subset of abs in patient 2246 could play 
a potential pathogenic role. We performed the affinity purification of MOG-specific abs by 
using human MOG, this allowed us to get rid of the abs that recognize only S42, which are 
not relevant in our patient since this amino acid is replaced by P42 in hMOG. The affinity 
purified antibody fraction obtained from this patient was still able to bind to rat MOG both in 
our CBA as well as to myelin in rat brains. Abs to MOG in patient 1771 showed binding to the 
CC’ loop of MOG. These abs were also affinity purified and used in our in vivo experiments. 
This is to our knowledge the first time that the in vivo pathogenicity of abs to MOG is 
investigated by using human abs recognizing the CC’loop on hMOG.  
 
 Repertoire of abs to MOG  4.4
The ELISA used to screen patient sera in this study was performed by using MOG produced 
in a human cell system. The protein was site-specific biotinylated and then bound to the 
ELISA plate in the same way as it is oriented on the cell membrane. This immunoassay 
based on the streptavidin-biotin system allowed higher sensitivity when compared to the 
conventional assay. Even though it is common view that only CBAs can identify abs to MOG 
that may have a pathogenic role in vivo (Brehm, Piddlesden et al. 1999, Ohtani, Kohyama et 
al. 2011), a direct comparison between a CBA and a streptavidin-based ELISA has to our 
knowledge not yet been done before. We analyzed a total of 116 patients with both assays 
and found that even by using this highly sensitive ELISA we could not identify all anti-MOG 
positive patients that scored positive in our CBA: 5 of 116 patients were positive in both 
assays, while two patients tested positive only by ELISA. The lack of correlation of the results 
we obtained with these two different methods strongly suggests the existence of a broad 
repertoire of MOG-specific abs in at least a subset of patients. Our data show that this MOG 
ELISA can be useful to predict whether abs to MOG from patients that scored positive in a 
CBA can be affinity purified with recombinantly produced MOG: abs from patients 1771 and 
2246 that scored positive in both assays, similarly to the mAb 8-18C5, could be affinity 
purified while the affinity purification of abs from patient 3202, who scored negative in the 
ELISA, did not succeed. In addition, our analysis provides direct evidence that a subset of 
anti-MOG positive patients have autoantibodies able to bind both the soluble recombinant 
protein as well as the cell-bound protein. Abs with these features have not been described in 
patients before, while the murine mAb 8-18C5 has these properties. Abs to MOG in some 
patients (Haase, Guggenmos et al. 2001) as well as the mAb Y11 (Brehm, Piddlesden et al. 
1999) are able to bind both linear MOG peptides as well as cell-bound MOG but the 
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pathogenic potential has been investigated only for the latter (Piddlesden, Lassmann et al. 
1993). The affinity of the purified abs to MOG was lower than the one observed for the mAb 
8-18C5 in the ELISA, however, they are still considered high affinity abs since their KD value 
was in the low nanomolar range. 
To investigate the pathogenic effects of MOG-specific abs in vivo we used, beside the affinity 
purification, an additional experimental approach: we isolated from patient 2246, both MOG-
specific B cells directly ex vivo as well as PBMCs which were stimulate in vitro to differentiate 
to antibody-secreting cells. This procedure was performed by using fluorescently labeled 
human and mouse MOG tetramers. The isolated cells were single-cell sorted and used to 
generate recombinant abs. Antigen-specific B cells circulate at very low frequency in 
peripheral blood and proliferate at a very low rate under steady-state conditions 
(Lanzavecchia and Sallusto 2009, Yoshida, Mei et al. 2010), therefore their identification can 
be challenging. We chose to use antigen tetramers since they determine an increase of the 
avidity of BCR labeling and of the brightness of staining. Moreover, the employment of 
fluorescently labeled streptavidin eliminates the need to modify the antigen with a 
fluorophore, a procedure that can cause epitope destruction. Our tetramers bound to MOG-
specific B lymphocytes from transgenic knock-in mice (Litzenburger, Fässler et al. 1998), 
suggesting that the recombinant MOG we used for tetramer formation exhibits the correct 
folding. Since we wanted to generate abs reactive against rodent MOG to use in our animal 
model, we used also a mMOG tetramer and single cell-sorted in vitro stimulated B cells. 
MOG-specific B cells in patient 2246 were mainly of the memory subtype, moreover, we 
could identify also a small proportion of early plasmablasts, which still carry their BCR on the 
surface. The in vitro stimulated B cells from this patient produced abs that showed anti- MOG 
reactivity in our CBA. In addition, we used a hMOG tetramer to isolate MOG-specific B cells 
directly from the peripheral blood of this patient. Also here we could identify a small 
proportion of cells belonging to the memory subtype. In total, we generated from the single 
cells sorted cells five recombinant abs. Four out of five of these abs showed reactivity 
against MOG by ELISA, but did not bind to MOG in our CBA. In addition, they showed cross-
reactivity to other antigens produced in the same human cell system as MOG. The 
autoreactivity we observed reminds of findings obtained with human immunoglobulins 
generated from randomly selected B cells: about 20 % of all abs produced by human mature 
B-lymphocytes are autoreactive and 4 % of these are polyreactive (Wardemann, Yurasov et 
al. 2003). Abs with these features are produced by circulating B cells that escaped the first 
BCR-dependent bone marrow selection checkpoint (Wardemann, Yurasov et al. 2003), a 
mechanism that triggers apoptosis or reediting for autoreactive BCR (Meffre and Wardemann 
2008). 
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 Pathogenicity of abs to MOG  4.5
Our study shows, to our knowledge for the first time, that MOG-specific abs affinity purified 
from the blood of two patients with demyelinating diseases were pathogenic in animals. This 
reveals that abs to MOG are not only a biomarker that helps to stratify patients with 
inflammatory diseases of the CNS. While our findings in index patient 1819 suggest a 
potential pathogenic role of abs to MOG, with here now show a direct proof of their 
pathogenicity in patients 2246 and 1771. Previous transfer studies, performed with 
concentrated sera from MS patients, showed that abs to MOG can exacerbate CNS damage 
and cellular immunity has been suggested as the main effector mechanism (Zhou, 
Srivastava et al. 2006). These results are difficult to interpret because pathogenicity could be 
caused by pathogenic compounds beyond abs to MOG. IgG from NMO patients that tested 
positive for abs to MOG can directly damage myelin in situ, independent of preexisting 
disease and of complement activation (Saadoun, Waters et al. 2014). These data strongly 
suggest that abs to MOG from different patients can exert their pathogenicity by using 
different effector mechanisms. The affinity purified abs from both patients tested positive for 
anti-MOG reactivity in our CBA and induced EAE exacerbation in Lewis rats. In addition, the 
histopathological analysis of rats who received affinity purified abs from patient 2246 reveals 
two important finding: first, the demyelination observed in these animals is complement 
mediated; second, MOG-specific abs are able to enhance in the CNS the local activation of 
MOG-specific T cells. Based on these findings, further experiments need to be performed in 
order to clarify whether MOG-specific B cells can also mediate demyelination in conjunction 
with T cells with another antigen specificity. MOG lesions in this study were characterized by 
a massive leucocyte infiltration, similarly to a recent finding (Flach, Litke et al. 2016). While in 
this latter case no disease relevant MOG abs mediated demyelination was observed, the 
injection of the abs from our patient induced a subpial demyelination. This was also present 
at the level of the optic nerve and consequently suggests that these abs exert a pathogenic 
role in this patient who was diagnosed with a severe ON. The injection of the r2246_D7 
antibody, obtained from MOG-specific B cells present in the peripheral blood of patient 2246, 
did not induce disease exacerbation in Lewis rats. This antibody showed reactivity against 
the extracellular domain of MOG but did not bind full length MOG in our CBA. The lack of 
pathogenic potential of this antibody in our in vivo experiments confirms that abs that do not 
recognize cell-bound MOG are not pathogenetically relevant in vivo.  
 Conclusions 4.6
Abs to MOG induce demyelination in different animal models, therefore, the identification of 
patients with MOG-specific abs may have diagnostic and therapeutic implications. In the first 
part of this study we show that abs to MOG can occur in patients with overlapping features of 
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NMOSD and MS. Our findings in index patient 1819 with MOG-associated encephalomyelitis 
suggest that abs to MOG can contribute to demyelination: these abs recognize conformation-
intact MOG; they can access the CNS via the locally opened blood-brain barrier; they are of 
the complement activating isotype; the histology in this patient resembles anti-MOG 
mediated demyelination in animals and MS type “pattern II”; the observed association 
between anti-MOG reactivity and clinical course and the improvement after IA indicate the 
presence of pathogenic abs. Similar findings were made subsequently also by other two 
groups (Di Pauli, Hoftberger et al. 2015, Jarius, Metz et al. 2016). We here show that abs to 
MOG can also be found in a small proportion of adult MS with a specific phenotype. Further 
studies have to clarify whether patients with MS and abs to MOG may are at higher risk of 
progressive disease. Our study reveals that especially patients with concomitant severe 
spinal cord and brainstem lesions should be tested for anti-MOG reactivity. The longitudinal 
analysis of abs to MOG we performed in these patients showed that the anti-MOG reactivity 
tends to fluctuate over time, indicating that repeated analysis may be helpful if clinical 
features are compatible with MOG-associated MS. In summary, the results from the first part 
of this study broaden the spectrum of diseases associated to MOG-specific abs and 
therefore support the emerging hypothesis that MOG-antibody associated diseases might be 
a separated entity.  
The role of abs to MOG in the pathogenesis of demyelinating diseases is still unresolved and 
the observation that only a subset of these abs recognizes both human and murine MOG, 
limits the employment of animal studies as experimental approach. Whether affinity purified 
and recombinant abs to MOG are pathogenic in vivo has not yet been investigated. These 
questions were addressed in the second part of this study. Abs to conformation-intact murine 
MOG were affinity purified from two adult patients diagnosed with ON. In addition, 
recombinant abs from one of this patient were generated. While affinity purified abs showed 
to be pathogenic in vivo by inducing demyelination and inflammation, recombinant abs did 
not induce any pathological effect. Taken together, our results with recombinant and affinity 
purified abs revealed a broad repertoire of abs against MOG, which occurred in the same 
patient (2246). Even though MOG-abs associated ON has been shown to have a  more 
favorable outcome than AQP4-abs associated NMOSD (Sato, Callegaro et al. 2014, 
Hoftberger, Sepulveda et al. 2015), the potential pathogenic role of abs to MOG in adult ON 
observed in this study is supported by the fact that MOG-abs associated ON is characterized 
by a more pronounced retinal atrophy (Havla, Kumpfel et al. 2016), optic nerve swelling 
(Ramanathan, Reddel et al. 2014) and by longer optic nerve lesions (Akaishi, Sato et al. 
2016, Ramanathan, Prelog et al. 2016) compared to patients with no abs to MOG. In 
conclusion, these findings strongly suggest abs to MOG as a potential emerging marker of 
ON.                                                                                                                                
References 
 
75 
5 References 
't Hart, B. A., J. D. Laman, et al. (2004). Modelling of multiple sclerosis: lessons learned in a 
non-human primate. The Lancet Neurology. 3: 588-597. 
Adelmann, M., J. Wood, et al. (1995). "The N-terminal domain of the myelin oligodendrocyte 
glycoprotein (MOG) induces acute demyelinating experimental autoimmune 
encephalomyelitis in the Lewis rat." J Neuroimmunol 63(1): 17-27. 
Akaishi, T., D. Sato, et al. (2016). "MRI and retinal abnormalities in isolated optic neuritis with 
myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study." J 
Neurol Neurosurg Psychiatry 87(4): 446-448. 
Beck, R., J. Trobe, et al. (2003). "High- and low-risk profiles for the development of multiple 
sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial." 
Arch Ophthalmol 121(7): 944-949. 
Beltran, E., B. Obermeier, et al. (2014). "Intrathecal somatic hypermutation of IgM in multiple 
sclerosis and neuroinflammation." Brain 137(Pt 10): 2703-2714. 
Berger, T., P. Rubner, et al. (2003). "Antimyelin antibodies as a predictor of clinically definite 
multiple sclerosis after a first demyelinating event." N Engl J Med 349(2): 139-145. 
Bourquin, C., A. Schubart, et al. (2003). "Selective unresponsiveness to conformational B cell 
epitopes of the myelin oligodendrocyte glycoprotein in H-2b mice." J Immunol 171(1): 455-
461. 
Bradl, M., T. Misu, et al. (2009). "Neuromyelitis optica: pathogenicity of patient 
immunoglobulin in vivo." Ann Neurol 66(5): 630-643. 
Brändle, S., B. Obermeier, et al. (2016). "Distinct oligoclonal band antibodies in multiple 
sclerosis recognize ubiquitous self-proteins." Proc Natl Acad Sci U S A 113(28): 7864-7869. 
Brehm, U., S. Piddlesden, et al. (1999). "Epitope specificity of demyelinating monoclonal 
autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG)." J 
Neuroimmunol 97(1-2): 9-15. 
Breithaupt, C., B. Schäfer, et al. (2008). "Demyelinating myelin oligodendrocyte glycoprotein-
specific autoantibody response is focused on one dominant conformational epitope region in 
rodents." J Immunol 181(2): 1255-1263. 
References 
 
76 
Brilot, F., R. C. Dale, et al. (2009). "Antibodies to native myelin oligodendrocyte glycoprotein 
in children with inflammatory demyelinating central nervous system disease." Ann Neurol 
66(6): 833-842. 
Brunner, C., H. Lassmann, et al. (1989). "Differential ultrastructural localization of myelin 
basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-
phosphodiesterase in the CNS of adult rats." J Neurochem 52(1): 296-304. 
Clements, C., H. Reid, et al. (2003). "The crystal structure of myelin oligodendrocyte 
glycoprotein, a key autoantigen in multiple sclerosis." Proc Natl Acad Sci 100(19): 11059-
11064. 
Cohen, J. A., A. J. Coles, et al. (2012). "Alemtuzumab versus interferon beta 1a as first-line 
treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled 
phase 3 trial." The Lancet 380(9856): 1819-1828. 
Confavreux, C., S. Vukusic, et al. (2000). "Relapses and progression of disability in multiple 
sclerosis." N Engl J Med 343(20): 1430-1438. 
Dale, R., E. Tantsis, et al. (2014). "Antibodies to MOG have a demyelination phenotype and 
affect oligodendrocyte cytoskeleton." 
Delarasse, C., P. Daubas, et al. (2003). "Myelin/oligodendrocyte glycoprotein-deficient 
(MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice." J Clin 
Invest 112(4)):544-553 
Derfuss, T., K. Parikh, et al. (2009). "Contactin-2/TAG-1-directed autoimmunity is identified in 
multiple sclerosis patients and mediates gray matter pathology in animals." Proc Natl Acad 
Sci U S A 106(20): 8302-8307. 
Di Pauli, F., R. Hoftberger, et al. (2015). "Fulminant demyelinating encephalomyelitis: 
Insights from antibody studies and neuropathology." Neurol Neuroimmunol Neuroinflamm 
2(6): e175. 
Di Pauli, F., S. Mader, et al. (2011). "Temporal dynamics of anti-MOG antibodies in CNS 
demyelinating diseases." Clin Immunol 138(3): 247-254. 
Durocher, Y., S. Perret, et al. (2002). "High-level and high-throughput recombinant protein 
production by transient transfection of suspension-growing human 293-EBNA1 cells." Nucleic 
Acids Res 30(2): E9. 
References 
 
77 
Fernandez-Carbonell, C., D. Vargas-Lowy, et al. (2015). "Clinical and MRI phenotype of 
children with MOG antibodies." Mult Scler 22(2): 174-184. 
Filippidou, N., G. Krashias, et al. (2016). "The association between IgG and IgM antibodies 
against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in 
patients with multiple sclerosis." Mol Immunol 75: 161-167. 
Fischer, M. T., I. Wimmer, et al. (2013). "Disease-specific molecular events in cortical 
multiple sclerosis lesions." Brain 136(Pt 6): 1799-1815. 
Flach, A. C., T. Litke, et al. (2016). "Autoantibody-boosted T-cell reactivation in the target 
organ triggers manifestation of autoimmune CNS disease." Proc Natl Acad Sci U S A 
113(12): 3323-3328. 
Genain, C. P., M. H. Nguyen, et al. (1995). "Antibody facilitation of multiple sclerosis-like 
lesions in a nonhuman primate." J. Clin. Invest. 96(6): 2966-2974. 
Gori, F., B. Mulinacci, et al. (2011). "IgG and IgM antibodies to the refolded MOG(1-125) 
extracellular domain in humans." J Neuroimmunol 233(1-2): 216-220. 
Guler, E., E. Kaptanoglu, et al. (2012). "Autoantibodies are not associated with familial 
mediterranean fever." Acta Reumatol Port 37(2): 144-148. 
Haase, C., J. Guggenmos, et al. (2001). "The fine specificity of the myelin oligodendrocyte 
glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy 
controls." J Neuroimmunol 114(1-2): 220-225. 
Hampe, C., L. Petrosini, et al. (2013). "Monoclonal antibodies to 65kDa glutamate 
decarboxylase induce epitope specific effects on motor and cognitive functions in rats." 
Orphanet J Rare Dis. 
Hauser, S., E. Waubant, et al. (2008). "B-cell depletion with rituximab in relapsing-remitting 
multiple sclerosis." N Engl J Med. 358(7): 676-688. 
Hauser, S. L., G. Comi, et al. (2015). "Efficacy and safety of ocrelizumab in relapsing multiple 
sclerosis - results of the interferon-beta-1a-controlled, double-blind, Phase III OPERA I and II 
studies." Mult Scler 21: 61-62 [Abstract 190]. 
Havla, J., T. Kumpfel, et al. (2016). "Myelin-oligodendrocyte-glycoprotein (MOG) 
autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal 
degeneration." J Neurol. 
References 
 
78 
Heigl, F., R. Hettich, et al. (2013). "Immunoadsorption in steroid-refractory multiple sclerosis: 
clinical experience in 60 patients." Atheroscler Suppl 14(1): 167-173. 
Hickman, S., C. Dalton, et al. (2002). "Management of acute optic neuritis." Lancet 
360(9349): 1953-1962. 
Hoffmann, F. and E. Meinl (2014). "B cells in multiple sclerosis: good or bad guys?: An article 
for 28 May 2014 - World MS Day 2014." Eur J Immunol 44(5): 1247-1250. 
Hoftberger, R., M. Sepulveda, et al. (2015). "Antibodies to MOG and AQP4 in adults with 
neuromyelitis optica and suspected limited forms of the disease." Mult Scler 21(7): 866-874. 
Hohlfeld, R., K. Dornmair, et al. (2016). "The search for the target antigens of multiple 
sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational 
research." The Lancet Neurology 15(3): 317-331. 
Jarius, S., I. Metz, et al. (2016). "Screening for MOG-IgG and 27 other anti-glial and anti-
neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-
IgG-positive case." Mult Scler 22(12): 1541-1549. 
Jarius, S., K. Ruprecht, et al. (2016). "MOG-IgG in NMO and related disorders: a multicenter 
study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory 
features, treatment responses, and long-term outcome." J Neuroinflammation 13(1): 280. 
Jarius, S. and B. Wildemann (2010). "AQP4 antibodies in neuromyelitis optica: diagnostic 
and pathogenetic relevance." Nat Rev Neurol 6(7)):383-392. 
Johns, T. and C. Bernard (1997). "Binding of complement component Clq to myelin 
oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation." Mol 
Immunol 34(1): 33-38. 
Kebir, H., K. Kreymborg, et al. (2007). "Human TH17 lymphocytes promote blood-brain 
barrier disruption and central nervous system inflammation." Nat Med 13(10): 1173-1175. 
Keegan, M., F. König, et al. (2005). "Relation between humoral pathological changes in 
multiple sclerosis and response to therapeutic plasma exchange." The Lancet 366(9485): 
579-582. 
Kim, S. M., M. R. Woodhall, et al. (2015). "Antibodies to MOG in adults with inflammatory 
demyelinating disease of the CNS." Neurol Neuroimmunol Neuroinflamm 2(6): e163. 
References 
 
79 
Kinzel, S., K. Lehmann-Horn, et al. (2016). "Myelin-reactive antibodies initiate T cell-
mediated CNS autoimmune disease by opsonization of endogenous antigen." Acta 
Neuropathol 132(1): 43-58. 
Kitley, J., M. I. Leite, et al. (2013). "Longitudinally extensive transverse myelitis with and 
without aquaporin 4 antibodies." JAMA Neurol 70(11): 1375-1381. 
Kitley, J., P. Waters, et al. (2014). "Neuromyelitis optica spectrum disorders with aquaporin-4 
and myelin-oligodendrocyte glycoprotein antibodies: a comparative study." JAMA Neurol 
71(3): 276-283. 
Kitley, J., M. Woodhall, et al. (2012). "Myelin-oligodendrocyte glycoprotein antibodies in 
adults with a neuromyelitis optica phenotype." Neurology 79(12): 1273-1277. 
Krumbholz, M., T. Derfuss, et al. (2012). "B cells and antibodies in multiple sclerosis 
pathogenesis and therapy." Nat Rev Neurol 8(11): 613-623. 
Krumbholz, M. and E. Meinl (2014). "B cells in MS and NMO: pathogenesis and therapy." 
Semin Immunopathol 36(3): 339-350. 
Krupp, L., M. Tardieu, et al. (2013). "International Pediatric Multiple Sclerosis Study Group 
criteria for pediatric multiple sclerosis and immune-mediated central nervous system 
demyelinating disorders: revisions to the 2007 definitions." Mult Scler. 19(10): 1261-1267. 
Kuhle, J., C. Pohl, et al. (2007). "Lack of association between antimyelin antibodies and 
progression to multiple sclerosis." N Engl J Med. 356(4): 371-378. 
Kumar, H., Y. Kumagai, et al. (2009). "Involvement of the NLRP3 inflammasome in innate 
and humoral adaptive immune responses to fungal beta-glucan." J Immunol 183)((12): 8061-
8067. 
Kutzelnigg, A., C. F. Lucchinetti, et al. (2005). "Cortical demyelination and diffuse white 
matter injury in multiple sclerosis." Brain 128(Pt 11): 2705-2712. 
Lalive, P. H., M. G. Hausler, et al. (2011). "Highly reactive anti-myelin oligodendrocyte 
glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in 
children." Mult Scler 17(3): 297-302. 
Lalive, P. H., T. Menge, et al. (2006). "Antibodies to native myelin oligodendrocyte 
glycoprotein are serologic markers of early inflammation in multiple sclerosis." Proc Natl 
Acad Sci U S A 103(7): 2280-2285. 
References 
 
80 
Lanzavecchia, A. and F. Sallusto (2009). "Human B cell memory." Curr Opin Immunol 21(3): 
298-304. 
Lassmann, H., C. Brunner, et al. (1988). "Experimental allergic encephalomyelitis: the 
balance between encephalitogenic T lymphocytes and demyelinating antibodies determines 
size and structure of demyelinated lesions." Acta Neuropathol 75(6): 566-576. 
Lebar, R., C. Lubetzki, et al. (1986). "The M2 autoantigen of central nervous system myelin, 
a glycoprotein present in oligodendrocyte membrane." Clin Exp Immunol. 66(2): 423-434. 
Lennon, V., D. Wingerchuk, et al. (2004). "A serum autoantibody marker of neuromyelitis 
optica: distinction from multiple sclerosis." Lancet 364(9451): 2106-2112. 
Lindert, R., C. Haase, et al. (1999). "Multiple sclerosis: B- and T-cell responses to the 
extracellular domain of the myelin oligodendrocyte glycoprotein." Brain 122( Pt 11): 2089-
2100. 
Linington, C., M. Bradl, et al. (1988). "Augmentation of demyelination in rat acute allergic 
encephalomyelitis by circulating mouse monoclonal antibodies directed against a 
myelin/oligodendrocyte glycoprotein." Am J Pathol 130(3): 443-454. 
Linington, C. and H. Lassmann (1987). "Antibody responses in chronic relapsing 
experimental allergic encephalomyelitis: correlation of serum demyelinating activity with 
antibody titre to the myelin/oligodendrocyte glycoprotein (MOG)." J Neuroimmunol 17(1): 61-
69. 
Litzenburger, T., R. Fässler, et al. (1998). "B lymphocytes producing demyelinating 
autoantibodies: development and function in gene-targeted transgenic mice." J Exp Med. 
188(1): 169-180. 
Lucchinetti, C., W. Brück, et al. (2000). "Heterogeneity of multiple sclerosis lesions: 
implications for the pathogenesis of demyelination." Ann Neurol 7(3): 115-121. 
Lucchinetti, C., R. Mandler, et al. (2002). "A role for humoral mechanisms in the 
pathogenesis of Devic's neuromyelitis optica." Brain 125(Pt 7): 1450-1461. 
Mader, S., V. Gredler, et al. (2011). "Complement activating antibodies to myelin 
oligodendrocyte glycoprotein in neuromyelitis optica and related disorders." J 
Neuroinflammation 8: 184. 
References 
 
81 
Marta, C. B., A. R. Oliver, et al. (2005). "Pathogenic myelin oligodendrocyte glycoprotein 
antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology." Proc 
Natl Acad Sci U S A 102(39): 13992-13997. 
Masters, S., A. Simon, et al. (2009). "Horror autoinflammaticus: the molecular 
pathophysiology of autoinflammatory disease (*)." Annu Rev Immunol 27: 621-668. 
Mata, S., W. Borsini, et al. (2011). "IgM monoclonal gammopathy-associated neuropathies 
with different IgM specificity." Eur J Neurol 18(8): 1067-1073. 
Mayer, M. and E. Meinl (2012). "Glycoproteins as targets of autoantibodies in CNS 
inflammation: MOG and more." Ther Adv Neurol Disord 5(3): 147-159. 
Mayer, M. C., C. Breithaupt, et al. (2013). "Distinction and temporal stability of conformational 
epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different 
inflammatory central nervous system diseases." J Immunol 191(7): 3594-3604. 
McLaughlin, K. A., T. Chitnis, et al. (2009). "Age-dependent B cell autoimmunity to a myelin 
surface antigen in pediatric multiple sclerosis." J Immunol 183(6): 4067-4076. 
Meffre, E. and H. Wardemann (2008). "B-cell tolerance checkpoints in health and 
autoimmunity." Curr Opin Immunol 20(6): 632-638. 
Misu, T., R. Höftberger, et al. (2013). "Presence of six different lesion types suggests diverse 
mechanisms of tissue injury in neuromyelitis optica." Acta Neuropathologica 125(6): 815-827. 
Murphy, K., P. Travers, et al. (2009). "Janeway Immunobiology, 9th Edition." Garland 
Science. 
Nakashima, I., T. Takahashi, et al. (2011). "Transient increases in anti-aquaporin-4 antibody 
titers following rituximab treatment in neuromyelitis optica, in association with elevated serum 
BAFF levels." J Clin Neurosci 18(7): 997-998. 
Neuteboom, R., M. Boon, et al. (2008). "Prognostic factors after a first attack of inflammatory 
CNS demyelination in children." Neurology 71(13): 967-973. 
O'Connor, K. C., K. A. McLaughlin, et al. (2007). "Self-antigen tetramers discriminate 
between myelin autoantibodies to native or denatured protein." Nat Med 13(2): 211-217. 
Obermeier, B., R. Mentele, et al. (2008). "Matching of oligoclonal immunoglobulin 
transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis." Nat Med 14(6): 
688-693. 
References 
 
82 
Ohtani, S., K. Kohyama, et al. (2011). "Autoantibodies recognizing native MOG are closely 
associated with active demyelination but not with neuroinflammation in chronic EAE." 
Neuropathology 31(2): 101-111. 
Onur, H., H. Aral, et al. (2013). "Anti-CCP Antibodies Are Not Associated with Familial 
Mediterranean Fever in Childhood." Int J Rheumatol 2013(498581). 
Pelayo, R., M. Tintoré, et al. (2007). "Antimyelin antibodies with no progression to multiple 
sclerosis." N Engl J Med 356(4): 426-428. 
Pellkofer, H., M. Krumbholz, et al. (2011). "Long-term follow-up of patients with neuromyelitis 
optica after repeated therapy with rituximab." Neurology 76(15): 1310-1315. 
Pham-Dinh, D., M. Matteit, et al. (1993). "Myelin/oligodendrocyte glycoprotein is a member of 
a subset of the immunoglobulin superfamily encoded within the major histocompatibility 
complex." Proc. Natl. Acad. Sci. 90(17): 7990-7994. 
Piddlesden, S., H. Lassmann, et al. (1993). "The demyelinating potential of antibodies to 
myelin oligodendrocyte glycoprotein is related to their ability to fix complement." Am J Pathol 
143(2): 555-564. 
Pinna, D., D. Corti, et al. (2009). "Clonal dissection of the human memory B-cell repertoire 
following infection and vaccination." Eur J Immunol 39(5): 1260-1270. 
Probstel, A. K., K. Dornmair, et al. (2011). "Antibodies to MOG are transient in childhood 
acute disseminated encephalomyelitis." Neurology 77(6): 580-588. 
Ramanathan, S., K. Prelog, et al. (2016). "Radiological differentiation of optic neuritis with 
myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple 
sclerosis." Mult Scler 22(4): 470-482. 
Ramanathan, S., S. W. Reddel, et al. (2014). "Antibodies to myelin oligodendrocyte 
glycoprotein in bilateral and recurrent optic neuritis." Neurol Neuroimmunol Neuroinflamm 
1(4): e40. 
Ramaraj, T., T. Angel, et al. (2012). "Antigen-antibody interface properties: composition, 
residue interactions, and features of 53 non-redundant structures." Biochim Biophys Acta 
1824(3): 520-532. 
Reindl, M., F. Di Pauli, et al. (2013). "The spectrum of MOG autoantibody-associated 
demyelinating diseases." Nat Rev Neurol 9(8): 455-461. 
References 
 
83 
Reindl, M., C. Linington, et al. (1999). "Antibodies against the myelin oligodendrocyte 
glycoprotein and the myelin basic protein in multiple sclerosis and other neurological 
diseases: a comparative study." Brain 122(Pt 11): 2047-2056. 
Rostasy, K., S. Mader, et al. (2012). "Anti-myelin oligodendrocyte glycoprotein antibodies in 
pediatric patients with optic neuritis." Arch Neurol 69(6): 752-756. 
Saadoun, S., P. Waters, et al. (2010). "Intra-cerebral injection of neuromyelitis optica 
immunoglobulin G and human complement produces neuromyelitis optica lesions in mice." 
Brain 133(Pt 2): 349-361. 
Saadoun, S., P. Waters, et al. (2014). "Neuromyelitis optica MOG-IgG causes reversible 
lesions in mouse brain." Acta Neuropathol Commun 2: 35. 
Saini, H., R. Rifkin, et al. (2013). "Passively transferred human NMO-IgG exacerbates 
demyelination in mouse experimental autoimmune encephalomyelitis." BMC Neurol 13(104). 
Sato, D. K., D. Callegaro, et al. (2014). "Distinction between MOG antibody-positive and 
AQP4 antibody-positive NMO spectrum disorders." Neurology 82(6): 474-481. 
Schluesener, H., R. Sobel, et al. (1987). "A monoclonal antibody against a myelin 
oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system 
autoimmune disease." J Immunol 139(12): 4016-4021. 
Serafini, B., B. Rosicarelli, et al. (2004). "Detection of ectopic B-cell follicles with germinal 
centers in the meninges of patients with secondary progressive multiple sclerosis." Brain 
Pathol 14(2): 164-174. 
Sorensen, P., S. Lisby, et al. (2014). "Safety and efficacy of ofatumumab in relapsing-
remitting multiple sclerosis: a phase 2 study." Neurology 82(7): 573-581. 
Spadaro, M., L. A. Gerdes, et al. (2016). "Autoantibodies to MOG in a distinct subgroup of 
adult multiple sclerosis." Neurol Neuroimmunol Neuroinflamm 3(5): e257. 
Spadaro, M., L. A. Gerdes, et al. (2015). "Histopathology and clinical course of MOG-
antibody-associated encephalomyelitis." Ann Clin Transl Neurol 2(3): 295-301. 
Spadaro, M. and E. Meinl (2016). "Detection of Autoantibodies Against Myelin 
Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases." Methods Mol Biol. 
1304: 99-104. 
Suwannalai, P., A. Willemze, et al. (2011). "The fine specificity of IgM anti-citrullinated protein 
antibodies (ACPA) is different from that of IgG ACPA." Arthritis Res Ther 13(6): R195. 
References 
 
84 
Titulaer, M. J., R. Hoftberger, et al. (2014). "Overlapping demyelinating syndromes and anti-
N-methyl-D-aspartate receptor encephalitis." Ann Neurol 75(3): 411-428. 
Traka, M., J. R. Podojil, et al. (2016). "Oligodendrocyte death results in immune-mediated 
CNS demyelination." Nat Neurosci 19(1): 65-74. 
Trebst, C., S. Jarius, et al. (2014). "Update on the diagnosis and treatment of neuromyelitis 
optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)." J Neurol 
261(1): 1-16. 
von Büdingen, H., F. Mei, et al. (2015). "The myelin oligodendrocyte glycoprotein directly 
binds nerve growth factor to modulate central axon circuitry." J Cell Biol 210(6): 891-898. 
Von Büdingen, H. C., M. Gulati, et al. (2010). "Clonally expanded plasma cells in the 
cerebrospinal fluid of patients with central nervous system autoimmune demyelination 
produce "oligoclonal bands"." J Neuroimmunol 218(1-2): 134-139. 
Wardemann, H., S. Yurasov, et al. (2003). "Predominant autoantibody production by early 
human B cell precursors." Science 301(5638): 1374-1377. 
Wingerchuk, D., Lennon VA, et al. (2007). "The spectrum of neuromyelitis optica." Lancet 
Neurol 6(9): 805-815. 
Wingerchuk, D., Lennon VA, et al. (2006). "Revised diagnostic criteria for neuromyelitis 
optica." Neurology 66(10): 1485-1489. 
Wu, X., M. Zhou, et al. (2013). "Myelin oligodendrocyte glycoprotein induces aquaporin-4 
autoantibodies in mouse experimental autoimmune encephalomyelitis." J Neuroimmunol 
261(1-2): 1-6. 
Xiao, B., C. Linington, et al. (1991). "Antibodies to myelin-oligodendrocyte glycoprotein in 
cerebrospinal fluid from patients with multiple sclerosis and controls." J Neuroimmunol 31(2): 
91-96. 
Yoshida, M., Y. Tamura, et al. (2000). "Immusorba TR and Immusorba PH: basics of design 
and features of functions. 1998." Ther Apher 4(2): 127-134. 
Yoshida, T., H. Mei, et al. (2010). "Memory B and memory plasma cells." Immunol Rev. 
237(1): 117-139. 
Zamvil, S. and A. Slavin (2015). "Does MOG Ig-positive AQP4-seronegative opticospinal 
inflammatory disease justify a diagnosis of NMO spectrum disorder?" Neurol Neuroimmunol 
Neuroinflamm 2(1): e62. 
  
85 
Zhou, D., R. Srivastava, et al. (2006). "Identification of a pathogenic antibody response to 
native myelin oligodendrocyte glycoprotein in multiple sclerosis." Proc Natl Acad Sci U S A 
103(50): 19057-19062. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Abbreviations 
 
86 
6 List of Abbreviations 
Abs   Antibodies         
Amp   Ampicillin         
BCA   Bicinchoninic acid       
BCR   B-cell receptor       
BSA   Bovine serum albumin       
CIS   Clinically isolated syndrom     
CSF   Cerebrospinal fluid       
DMSO   Dimethyl sulfoxide       
DNA   Deoxyribonucleic acid       
EAE   Experimental autoimmune encephalomyelitis   
EBNA   Epstein-Barr virus nuclear antigen     
EDTA   Ethylenediaminetetraacetic acid     
EGFP   Esmerald green fluorescent protein     
ELISA   Enzyme-linked immunosorbent assay     
FCS   Fetal calf serum       
FITC   Fluorescein isothiocyanate     
HC   Healthy controls       
HEK 293   Human embryonic kidney cell line     
HeLa   Cervical cancer cell line Henrietta Lacks   
His-Tag   Polyhistidine tag       
hMOG   Human MOG       
HRP   Horseradish peroxidase       
Kan   Kanamycin         
LB media   Luria-Bertani media       
LDS   Lithium dodecyl sulfate       
mAb   Monoclonal antibody       
MFI   Mean fluorescence intensity     
MOG   Myelin oligodendrocyte glycoprotein     
MRI   Magnetic resonance imaging     
MS   Multiple sclerosis       
NaOH   Sodium hydroxide       
NF   Neurofascin         
NHS   N-hydroxysuccinimide       
NIND   Non inflammatory neurological diseases    
Ni-NTA   Nickel-nitrilotriacetic acid     
NMOSD   Neuromyelitis optica spectrum disorders   
OCB   Oligoclonal band       
omgP   Oligodendrocyte myelin glycoprotein     
ON   Optic Neurities       
PBS   Phosphate buffered saline     
PBST   Phosphate buffered saline with Tween-20   
PCR   Polymerase chain reaction     
PE   Phycoerythrin       
PLEX   Plasma exchange       
PVDF   Polyvinylidene fluoride       
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RRMS   Relapsing-remitting multiple sclerosis     
RT-PCR   Reverse-transcript polymerase chain reaction   
SDS-PAGE   Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SPMS   Secondary-progressive multiple sclerosis   
TMB   3,3',5,5'-Tetramethylbenzidine     
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